Microarray analysis of bone marrow-derived macrophage cells treated with Kdo2-lipid A (KLA) and ATP

Search by fold change ratio | Search by KEGG pathway | Search by LIPID MAPS lipid pathway

Kdo2-Lipid A / ATP gene array data - treatment:control ratios

KEGG pathway: Pathways in cancer (mmu05200)

Legend:graph_icon: View data/graphs for replicates
Gene symbol    Time course plot Accession Description Treatment 15min 30min 1hr 2hr 4hr 8hr 20hr
Abl1
KLA  ATP  ATP+KLA
 AK083248 adult male hippocampus cDNA, RIKEN full-length enriched library, clone:C630031E05 product:v-abl Abelson murine leukemia oncogene 1, full insert sequence. [AK083248] KLA 1.07 1.07 .92 1.01 .98 1.07 .98
ATP .98 .99 .94 .90 .99 1.07 1.04
KLA/ATP 1.04 1.01 1.03 .98 .97 .95 .99
Abl1
KLA  ATP  ATP+KLA
 NM_009594 c-abl oncogene 1, receptor tyrosine kinase (Abl1), transcript variant 2, mRNA [NM_009594] KLA .63 .62 .65 .71 .96 1.17 1.05
ATP 1.01 1.16 1.03 1.14 1.12 .98 .98
KLA/ATP .66 .64 .67 .73 .84 .90 1.05
AK019932
KLA  ATP  ATP+KLA
 AK019932 adult male pituitary gland cDNA, RIKEN full-length enriched library, clone:5330434N09 product:inferred: transmembrane receptor frizzled 5 {Mus musculus}, full insert sequence [AK019932] KLA .99 .94 .97 .98 .96 .99 1.03
ATP 1.02 1.07 1.02 .97 1.00 .98 .93
KLA/ATP .93 .99 .91 1.04 1.02 1.01 1.00
AK038264
KLA  ATP  ATP+KLA
 AK038264 16 days neonate thymus cDNA, RIKEN full-length enriched library, clone:A130091A22 product:unclassifiable, full insert sequence. [AK038264] KLA .96 1.05 1.06 .95 .98 1.07 1.05
ATP 1.01 1.02 .99 .98 .96 1.02 1.00
KLA/ATP 1.06 .96 .98 .97 1.05 1.08 1.39
AK044510
KLA  ATP  ATP+KLA
 AK044510 adult retina cDNA, RIKEN full-length enriched library, clone:A930017M14 product:laminin, alpha 1, full insert sequence. [AK044510] KLA .96 1.07 1.03 1.05 1.00 1.06 1.16
ATP 1.04 1.04 1.04 1.04 1.05 1.08 1.01
KLA/ATP .96 1.08 1.07 1.10 1.12 1.08 1.01
AK083781
KLA  ATP  ATP+KLA
 AK083781 12 days embryo spinal ganglion cDNA, RIKEN full-length enriched library, clone:D130007L03 product:unclassifiable, full insert sequence. [AK083781] KLA .97 1.00 1.07 .97 .99 .95 1.03
ATP 1.04 1.04 1.01 .99 .95 .97 1.08
KLA/ATP .96 1.04 1.02 .97 1.00 1.07 1.02
Akt1
KLA  ATP  ATP+KLA
 NM_009652 thymoma viral proto-oncogene 1 (Akt1), mRNA [NM_009652] KLA .80 .80 .75 .75 .71 .70 .82
ATP 1.00 1.02 .76 .85 .76 .68 .84
KLA/ATP .82 .80 .64 .68 .67 .61 .72
Akt2
KLA  ATP  ATP+KLA
 NM_007434 thymoma viral proto-oncogene 2 (Akt2), transcript variant 2, mRNA [NM_007434] KLA 1.45 1.49 1.81 1.61 1.83 1.17 .92
ATP 1.12 1.12 1.00 1.28 1.20 .94 1.06
KLA/ATP 1.48 1.70 1.69 1.58 1.57 1.32 1.27
Akt3
KLA  ATP  ATP+KLA
 NM_011785 thymoma viral proto-oncogene 3 (Akt3), mRNA [NM_011785] KLA 3.42 3.45 5.31 5.16 4.65 3.80 2.12
ATP 1.12 1.22 1.10 1.37 1.02 1.11 1.56
KLA/ATP 3.72 4.17 4.62 4.64 2.74 2.05 3.82
Apc
KLA  ATP  ATP+KLA
 NM_007462 adenomatosis polyposis coli (Apc), mRNA [NM_007462] KLA .98 .94 .91 .86 .83 .91 1.01
ATP 1.06 1.16 1.04 .97 1.63 1.50 1.25
KLA/ATP 1.01 1.01 .92 .88 1.22 1.46 1.21
Apc2
KLA  ATP  ATP+KLA
 NM_011789 adenomatosis polyposis coli 2 (Apc2), mRNA [NM_011789] KLA 1.05 1.15 1.12 1.13 1.07 1.11 1.08
ATP 1.04 .97 1.15 1.27 1.12 1.09 1.16
KLA/ATP 1.12 1.20 1.21 1.24 1.25 1.13 1.04
Appl1
KLA  ATP  ATP+KLA
 NM_145221 adaptor protein, phosphotyrosine interaction, PH domain and leucine zipper containing 1 (Appl1), mRNA [NM_145221] KLA 3.57 3.58 3.06 2.90 1.97 .97 .94
ATP 1.02 1.05 1.12 .86 .96 .81 .73
KLA/ATP 3.31 3.71 3.74 2.76 1.93 .78 .71
Ar
KLA  ATP  ATP+KLA
 NM_013476 androgen receptor (Ar), mRNA [NM_013476] KLA 1.00 1.02 1.01 1.02 1.00 .99 1.01
ATP 1.00 1.00 1.01 1.00 1.01 1.00 1.01
KLA/ATP .99 .99 1.00 1.02 1.00 1.00 .99
Araf
KLA  ATP  ATP+KLA
 NM_009703 v-raf murine sarcoma 3611 viral oncogene homolog (Araf), mRNA [NM_009703] KLA .87 .80 .89 .93 1.10 1.19 1.16
ATP 1.09 1.11 1.19 1.18 .78 .53 1.18
KLA/ATP 1.00 .95 .99 .93 .63 .55 1.27
Arnt
KLA  ATP  ATP+KLA
 AK037762 16 days neonate thymus cDNA, RIKEN full-length enriched library, clone:A130047M16 product:aryl hydrocarbon receptor nuclear translocator, full insert sequence. [AK037762] KLA 1.01 .87 .97 .92 1.13 .91 1.00
ATP 1.16 1.22 1.22 .84 1.57 1.19 1.05
KLA/ATP 1.06 1.06 1.08 .95 1.40 1.18 1.06
Arnt
KLA  ATP  ATP+KLA
 NM_001037737 aryl hydrocarbon receptor nuclear translocator (Arnt), transcript variant 1, mRNA [NM_001037737] KLA 1.23 1.27 1.32 1.23 1.34 1.33 1.30
ATP 1.02 1.09 .96 .90 .99 1.33 1.38
KLA/ATP 1.30 1.28 1.05 1.12 1.07 1.64 1.89
Arnt
KLA  ATP  ATP+KLA
 U14333 aromatic hydrocarbon receptor nuclear translocator Arnt (ARNT) mRNA, complete cds. [U14333] KLA 1.78 1.78 1.78 1.85 1.64 1.71 1.40
ATP .96 1.05 1.37 1.24 1.19 2.13 2.37
KLA/ATP 1.72 1.87 1.87 1.83 1.53 2.53 3.65
Arnt2
KLA  ATP  ATP+KLA
 NM_007488 aryl hydrocarbon receptor nuclear translocator 2 (Arnt2), mRNA [NM_007488] KLA 1.06 1.02 1.01 1.02 1.02 1.02 .97
ATP 1.00 1.00 1.03 1.05 .96 1.05 1.23
KLA/ATP .99 .97 .99 .99 1.05 1.08 1.29
Axin1
KLA  ATP  ATP+KLA
 NM_009733 axin 1 (Axin1), mRNA [NM_009733] KLA .97 .91 1.14 1.08 1.23 1.21 1.07
ATP 1.08 1.06 .96 1.04 1.56 1.30 1.13
KLA/ATP 1.05 1.03 1.06 1.03 1.43 1.45 1.21
Axin2
KLA  ATP  ATP+KLA
 NM_015732 axin2 (Axin2), mRNA [NM_015732] KLA .91 .97 1.00 .97 1.00 .97 1.00
ATP .99 .97 .97 1.04 1.12 .98 1.01
KLA/ATP .98 .86 1.25 1.04 1.09 1.01 1.06
Bad
KLA  ATP  ATP+KLA
 AK029400 0 day neonate head cDNA, RIKEN full-length enriched library, clone:4833429M11 product:Bcl-associated death promoter, full insert sequence. [AK029400] KLA 1.15 1.22 1.26 1.31 1.40 1.67 1.59
ATP .95 1.06 1.12 1.06 .78 .89 1.27
KLA/ATP 1.25 1.39 1.33 1.29 1.11 .91 1.38
Bax
KLA  ATP  ATP+KLA
 NM_007527 Bcl2-associated X protein (Bax), mRNA [NM_007527] KLA 1.08 1.14 1.10 1.14 1.17 1.06 .92
ATP 1.06 1.05 1.02 1.25 1.26 .90 .86
KLA/ATP 1.11 1.19 1.30 1.34 1.34 .87 .71
BB229853
KLA  ATP  ATP+KLA
 BB229853 gb|BB229853 RIKEN full-length enriched, 3 days neonate thymus Mus musculus cDNA clone A630023O21 3. [BB229853] KLA 6.32 5.94 6.13 6.41 7.39 12.33 6.08
ATP .39 .24 .33 .38 1.18 5.75 2.85
KLA/ATP 2.27 2.02 3.25 4.04 7.11 10.22 13.93
BC010335
KLA  ATP  ATP+KLA
 BC010335 fibronectin 1, mRNA (cDNA clone IMAGE:3156499), **** WARNING: chimeric clone ****. [BC010335] KLA .94 .88 1.01 .99 .95 .95 1.07
ATP 1.06 .98 1.20 1.30 1.07 .97 .97
KLA/ATP .93 1.00 1.07 1.20 1.02 .96 .94
Bcl2
KLA  ATP  ATP+KLA
 NM_009741 B-cell leukemia/lymphoma 2 (Bcl2), transcript variant 1, mRNA [NM_009741] KLA .30 .26 .25 .25 .34 .38 .26
ATP .97 .89 1.50 1.04 .99 .29 .52
KLA/ATP .28 .26 .40 .33 .62 .29 .12
Bcl2
KLA  ATP  ATP+KLA
 NM_177410 B-cell leukemia/lymphoma 2 (Bcl2), transcript variant 2, mRNA [NM_177410] KLA .33 .33 .37 .42 .49 .46 .39
ATP 1.07 1.12 1.22 1.56 1.00 .38 .76
KLA/ATP .35 .34 .54 .89 .76 .36 .23
Bcl2l1
KLA  ATP  ATP+KLA
 NM_009743 Bcl2-like 1 (Bcl2l1), nuclear gene encoding mitochondrial protein, mRNA [NM_009743] KLA .99 1.02 1.10 1.16 1.27 .97 1.05
ATP 1.18 1.42 .81 1.26 1.51 .71 1.67
KLA/ATP 1.21 1.30 .66 1.15 1.31 1.17 1.59
Bcr
KLA  ATP  ATP+KLA
 NM_001081412 breakpoint cluster region homolog (Bcr), mRNA [NM_001081412] KLA 1.00 1.03 1.04 .98 .99 .98 .92
ATP 1.00 1.02 1.06 1.26 1.15 1.09 1.03
KLA/ATP 1.06 1.11 1.08 1.24 1.08 1.04 1.05
BI646741
KLA  ATP  ATP+KLA
 BI646741 gb|BI646741 603279769F1 NCI_CGAP_Mam3 Mus musculus cDNA clone IMAGE:5320025 5, mRNA sequence [BI646741] KLA .55 .54 .47 .54 .65 1.09 1.60
ATP 1.04 .99 .93 1.08 2.49 .79 .88
KLA/ATP .54 .49 .54 .60 1.21 .97 1.54
Bid
KLA  ATP  ATP+KLA
 NM_007544 BH3 interacting domain death agonist (Bid), mRNA [NM_007544] KLA 1.03 1.08 1.09 1.14 1.01 .99 .68
ATP 1.06 1.11 .97 .89 1.04 1.17 1.08
KLA/ATP .88 1.09 .92 1.06 1.16 1.28 1.56
Birc2
KLA  ATP  ATP+KLA
 NM_007465 baculoviral IAP repeat-containing 2 (Birc2), mRNA [NM_007465] KLA 4.63 4.59 3.77 2.79 2.32 2.07 1.84
ATP .95 .88 .84 .92 .76 1.34 1.28
KLA/ATP 4.70 4.93 4.13 2.60 1.34 1.60 2.31
Birc3
KLA  ATP  ATP+KLA
 BC011338 baculoviral IAP repeat-containing 3, mRNA (cDNA clone MGC:18386 IMAGE:3661563), complete cds [BC011338] KLA 5.48 5.46 4.94 4.16 4.91 3.36 3.74
ATP 1.05 1.08 4.21 4.28 2.59 2.55 1.57
KLA/ATP 6.78 8.91 11.01 4.87 2.28 2.12 3.66
Birc3
KLA  ATP  ATP+KLA
 NM_007464 baculoviral IAP repeat-containing 3 (Birc3), mRNA [NM_007464] KLA 17.83 15.88 13.48 11.14 11.79 6.90 6.10
ATP 1.14 1.16 1.70 4.07 5.00 6.33 2.41
KLA/ATP 14.77 16.44 19.09 13.91 8.27 6.22 7.73
Birc5
KLA  ATP  ATP+KLA
 NM_001012273 baculoviral IAP repeat-containing 5 (Birc5), transcript variant 3, mRNA [NM_001012273] KLA .41 .38 .29 .23 .13 .08 .06
ATP .95 .88 1.19 1.09 .67 .29 .05
KLA/ATP .38 .33 .41 .36 .27 .10 .04
Birc7
KLA  ATP  ATP+KLA
 AK053463 0 day neonate eyeball cDNA, RIKEN full-length enriched library, clone:E130019N06 product:weakly similar to BA261N11.1.3 (BACULOVIRAL IAP REPEAT-CONTAINING PROTEIN 7 (LIVIN), ISOFORM 3) (FRAGMENT) [Homo sapiens], full insert sequence [AK05 KLA 1.02 1.02 .93 1.01 .91 1.27 1.07
ATP 1.02 1.03 .99 .93 .96 .98 1.01
KLA/ATP 1.00 1.04 .97 .94 .91 .93 .92
Bmp2
KLA  ATP  ATP+KLA
 NM_007553 bone morphogenetic protein 2 (Bmp2), mRNA [NM_007553] KLA 1.18 1.19 1.30 1.16 1.02 1.07 .99
ATP 1.05 1.18 1.79 4.60 2.95 2.38 .96
KLA/ATP 1.26 1.52 1.77 2.64 1.78 1.47 .97
Bmp4
KLA  ATP  ATP+KLA
 NM_007554 bone morphogenetic protein 4 (Bmp4), mRNA [NM_007554] KLA 1.02 1.04 1.04 1.09 1.08 1.12 1.06
ATP .98 1.00 1.05 1.04 .94 .97 1.00
KLA/ATP .99 1.03 1.07 1.04 .99 .99 .97
Braf
KLA  ATP  ATP+KLA
 NM_139294 Braf transforming gene (Braf), mRNA [NM_139294] KLA 1.52 1.57 1.55 1.33 1.83 1.52 1.60
ATP 1.08 1.17 1.02 1.37 .95 1.15 .95
KLA/ATP 1.64 1.69 1.39 1.51 1.04 1.31 1.26
Brca2
KLA  ATP  ATP+KLA
 NM_009765 breast cancer 2 (Brca2), transcript variant 2, mRNA [NM_009765] KLA .25 .23 .23 .26 .28 .29 .24
ATP .94 .94 1.19 .68 .36 .30 .28
KLA/ATP .23 .22 .33 .31 .30 .23 .19
Casp3
KLA  ATP  ATP+KLA
 NM_009810 caspase 3 (Casp3), mRNA [NM_009810] KLA 1.66 1.94 2.47 2.61 3.01 2.96 1.44
ATP .90 .99 1.17 1.30 1.01 1.17 .86
KLA/ATP 1.55 1.87 2.40 2.35 2.27 2.84 2.52
Casp3
KLA  ATP  ATP+KLA
 U49929 ICE-like cysteine protease (Lice) mRNA, complete cds. [U49929] KLA 1.71 1.87 2.69 3.11 3.64 3.42 1.52
ATP 1.04 1.07 1.16 1.34 .98 1.27 .86
KLA/ATP 1.80 1.96 2.46 2.91 2.50 3.24 3.10
Casp8
KLA  ATP  ATP+KLA
 NM_009812 caspase 8 (Casp8), transcript variant 1, mRNA [NM_009812] KLA 2.41 2.53 3.20 3.26 2.75 2.78 1.57
ATP .91 .96 .66 .67 .54 1.53 1.52
KLA/ATP 2.47 2.52 2.08 2.41 1.41 2.50 2.77
Casp9
KLA  ATP  ATP+KLA
 NM_015733 caspase 9 (Casp9), mRNA [NM_015733] KLA .31 .31 .40 .66 .89 1.19 .91
ATP .88 .77 .91 .59 .43 .75 .93
KLA/ATP .26 .26 .30 .28 .80 1.06 .97
Cbl
KLA  ATP  ATP+KLA
 NM_007619 Casitas B-lineage lymphoma (Cbl), mRNA [NM_007619] KLA 1.23 1.22 1.54 1.84 2.25 2.58 2.75
ATP 1.04 1.12 1.07 1.53 1.55 2.12 3.23
KLA/ATP 1.23 1.20 1.22 1.44 1.31 1.88 6.28
Cblb
KLA  ATP  ATP+KLA
 AK045005 9.5 days embryo parthenogenote cDNA, RIKEN full-length enriched library, clone:B130018P07 product:hypothetical protein, full insert sequence. [AK045005] KLA 1.16 1.11 1.15 1.10 1.16 .98 .93
ATP 1.16 1.23 .98 1.28 1.34 .73 1.55
KLA/ATP 1.26 1.60 1.64 1.23 1.01 .91 1.05
Cblb
KLA  ATP  ATP+KLA
 AK084162 12 days embryo eyeball cDNA, RIKEN full-length enriched library, clone:D230004I05 product:unclassifiable, full insert sequence. [AK084162] KLA .97 .98 1.02 1.01 .84 1.02 1.03
ATP 1.03 1.02 .98 1.09 1.05 .96 .96
KLA/ATP 1.07 .95 .91 .98 .98 1.01 1.00
Cblc
KLA  ATP  ATP+KLA
 NM_023224 Casitas B-lineage lymphoma c (Cblc), mRNA [NM_023224] KLA 1.02 .98 1.01 1.02 1.00 .99 1.05
ATP .94 .95 .97 1.04 .99 .97 .99
KLA/ATP 1.00 1.01 .96 .97 .94 .92 .99
Ccdc6
KLA  ATP  ATP+KLA
 NM_001111121 coiled-coil domain containing 6 (Ccdc6), mRNA [NM_001111121] KLA 1.76 1.92 2.07 1.95 1.37 1.16 1.01
ATP 1.08 1.04 .78 .74 .59 .70 .85
KLA/ATP 2.03 1.87 1.38 1.33 .95 .82 .95
Ccnd1
KLA  ATP  ATP+KLA
 S78355 gb|Cyl-1=cyclin D1 [mice, BALB/c, brain, mRNA, 3737 nt]. [S78355] KLA .24 .23 .23 .24 .29 .47 .17
ATP 1.02 1.02 .88 .80 .52 .10 .21
KLA/ATP .27 .23 .22 .24 .27 .25 .14
Ccne1
KLA  ATP  ATP+KLA
 NM_007633 cyclin E1 (Ccne1), mRNA [NM_007633] KLA 1.13 1.14 1.13 .78 .51 .69 .55
ATP .92 .94 1.09 .93 .75 .71 .47
KLA/ATP 1.13 1.17 1.45 1.24 1.33 1.50 .85
Ccne2
KLA  ATP  ATP+KLA
 NM_001037134 cyclin E2 (Ccne2), transcript variant 1, mRNA [NM_001037134] KLA .34 .35 .42 .36 .35 .36 .26
ATP 1.02 1.11 1.01 .82 .58 .38 .23
KLA/ATP .36 .34 .44 .43 .41 .40 .25
Cdc42
KLA  ATP  ATP+KLA
 NM_009861 cell division cycle 42 homolog (S. cerevisiae) (Cdc42), mRNA [NM_009861] KLA 1.04 1.01 1.02 1.04 1.12 1.21 1.12
ATP 1.07 1.10 1.04 1.06 1.02 .95 1.14
KLA/ATP .94 1.04 1.01 .97 .95 1.02 1.25
Cdh1
KLA  ATP  ATP+KLA
 NM_009864 cadherin 1 (Cdh1), mRNA [NM_009864] KLA 1.03 1.03 .99 .94 .95 .97 .99
ATP 1.04 1.06 1.06 .96 .99 1.07 .95
KLA/ATP 1.02 1.07 1.00 .90 .93 .94 .98
Cdk2
KLA  ATP  ATP+KLA
 NM_016756 cyclin-dependent kinase 2 (Cdk2), transcript variant 2, mRNA [NM_016756] KLA .68 .67 .62 .63 .60 .74 .73
ATP 1.02 1.14 .91 .92 .68 .71 .65
KLA/ATP .67 .64 .64 .64 .61 .74 .62
Cdk4
KLA  ATP  ATP+KLA
 NM_009870 cyclin-dependent kinase 4 (Cdk4), mRNA [NM_009870] KLA .66 .72 .65 .55 .46 .50 .71
ATP 1.03 1.02 .53 .65 .66 .63 .75
KLA/ATP .78 .61 .31 .42 .44 .62 .43
Cdk6
KLA  ATP  ATP+KLA
 AK030810 adult male thymus cDNA, RIKEN full-length enriched library, clone:5830411I20 product:unclassifiable, full insert sequence [AK030810] KLA 1.05 .96 .67 .51 .48 .49 .45
ATP 1.02 .91 .78 .49 .50 .47 .44
KLA/ATP 1.01 .89 .65 .40 .36 .26 .49
Cdk6
KLA  ATP  ATP+KLA
 NM_009873 cyclin-dependent kinase 6 (Cdk6), mRNA [NM_009873] KLA 2.63 2.36 2.14 1.80 1.55 1.32 1.03
ATP 1.11 1.21 1.06 1.23 .94 1.30 2.08
KLA/ATP 2.58 2.69 2.24 2.25 1.38 .85 3.00
Cdkn1a
KLA  ATP  ATP+KLA
 NM_007669 cyclin-dependent kinase inhibitor 1A (P21) (Cdkn1a), transcript variant 1, mRNA [NM_007669] KLA 4.72 4.90 4.96 3.73 2.11 1.14 1.02
ATP 1.14 1.52 .95 1.69 1.47 2.21 .50
KLA/ATP 5.99 7.08 3.86 6.37 3.00 2.55 2.05
Cdkn1b
KLA  ATP  ATP+KLA
 NM_009875 cyclin-dependent kinase inhibitor 1B (Cdkn1b), mRNA [NM_009875] KLA .81 .84 .84 .91 .93 .88 .97
ATP .99 1.09 .97 1.06 1.48 .94 .91
KLA/ATP .83 .91 1.04 1.36 1.48 1.06 1.09
Cdkn2a
KLA  ATP  ATP+KLA
 NM_009877 cyclin-dependent kinase inhibitor 2A (Cdkn2a), transcript variant 1, mRNA [NM_009877] KLA .95 .95 .86 .96 .91 .90 .75
ATP 1.00 .99 .95 .95 .97 .89 .77
KLA/ATP .95 .96 .92 .94 .90 .85 .76
Cdkn2b
KLA  ATP  ATP+KLA
 NM_007670 cyclin-dependent kinase inhibitor 2B (p15, inhibits CDK4) (Cdkn2b), mRNA [NM_007670] KLA .70 .75 .94 1.44 1.66 .55 .81
ATP 1.02 .89 1.00 .86 1.33 3.87 .57
KLA/ATP .71 .77 .91 .94 .74 1.64 1.17
Cebpa
KLA  ATP  ATP+KLA
 NM_007678 CCAAT/enhancer binding protein (C/EBP), alpha (Cebpa), mRNA [NM_007678] KLA .17 .18 .15 .16 .17 .33 .37
ATP 1.13 1.26 .92 1.72 1.70 .94 1.32
KLA/ATP .21 .18 .19 .36 .87 .81 .72
Chuk
KLA  ATP  ATP+KLA
 NM_007700 conserved helix-loop-helix ubiquitous kinase (Chuk), mRNA [NM_007700] KLA 1.32 1.42 1.41 1.17 1.32 1.22 1.40
ATP 1.22 1.30 1.18 .97 1.02 1.00 1.37
KLA/ATP 1.56 1.61 1.21 1.09 .83 .84 1.17
Cks1b
KLA  ATP  ATP+KLA
 NM_016904 CDC28 protein kinase 1b (Cks1b), mRNA [NM_016904] KLA .63 .61 .51 .46 .26 .18 .18
ATP .92 .90 1.37 1.39 1.12 .57 .11
KLA/ATP .56 .59 .71 .75 .63 .26 .06
Cks2
KLA  ATP  ATP+KLA
 NM_025415 CDC28 protein kinase regulatory subunit 2 (Cks2), mRNA [NM_025415] KLA .52 .50 .48 .49 .35 .27 .19
ATP .92 .98 1.53 1.98 2.18 1.57 .12
KLA/ATP .48 .49 .81 1.20 2.25 1.82 .29
Col4a1
KLA  ATP  ATP+KLA
 NM_009931 collagen, type IV, alpha 1 (Col4a1), mRNA [NM_009931] KLA 1.13 1.19 1.12 1.09 1.04 .89 .90
ATP 1.01 1.17 1.02 1.04 .91 .89 .97
KLA/ATP 1.14 1.24 1.03 1.15 .95 .86 1.01
Col4a2
KLA  ATP  ATP+KLA
 NM_009932 collagen, type IV, alpha 2 (Col4a2), mRNA [NM_009932] KLA 1.30 1.45 1.54 1.40 1.71 1.71 2.12
ATP 1.09 1.07 .98 1.03 .92 1.21 1.42
KLA/ATP 1.45 1.53 1.24 1.29 1.16 1.57 3.31
Col4a3
KLA  ATP  ATP+KLA
 NM_007734 collagen, type IV, alpha 3 (Col4a3), mRNA [NM_007734] KLA 1.09 1.11 1.12 1.10 1.05 1.06 1.04
ATP 1.02 1.03 1.01 .99 1.01 1.07 1.07
KLA/ATP 1.04 1.13 1.01 1.09 1.02 .98 1.01
Col4a4
KLA  ATP  ATP+KLA
 NM_007735 collagen, type IV, alpha 4 (Col4a4), mRNA [NM_007735] KLA 1.35 1.29 1.33 1.39 1.30 1.18 .98
ATP 1.14 1.08 1.30 1.54 1.54 1.34 .93
KLA/ATP 1.37 1.41 1.70 1.88 1.67 1.29 1.19
Col4a5
KLA  ATP  ATP+KLA
 NM_007736 collagen, type IV, alpha 5 (Col4a5), mRNA [NM_007736] KLA 1.00 .95 .95 .82 .72 .58 .70
ATP 1.05 1.18 .98 .88 .56 .53 .57
KLA/ATP 1.04 1.05 .83 .82 .58 .49 .61
Col4a6
KLA  ATP  ATP+KLA
 NM_053185 collagen, type IV, alpha 6 (Col4a6), mRNA [NM_053185] KLA 1.06 1.04 1.00 1.07 .94 .93 .94
ATP .97 .96 1.18 1.10 1.07 1.04 .86
KLA/ATP 1.00 1.05 1.22 1.06 1.12 1.02 .93
Crebbp
KLA  ATP  ATP+KLA
 AK048818 0 day neonate cerebellum cDNA, RIKEN full-length enriched library, clone:C230072N21 product:hypothetical protein, full insert sequence [AK048818] KLA 1.44 1.19 1.26 1.25 1.25 1.36 1.24
ATP .98 .90 1.04 1.11 1.95 2.72 1.51
KLA/ATP 1.17 1.27 1.45 1.28 1.98 2.80 2.52
Crebbp
KLA  ATP  ATP+KLA
 NM_001025432 CREB binding protein (Crebbp), mRNA [NM_001025432] KLA .97 1.01 .98 1.06 1.05 .99 1.07
ATP 1.07 1.05 .96 1.01 1.15 1.14 1.00
KLA/ATP 1.01 .97 .97 1.00 1.03 1.23 1.13
Crebbp
KLA  ATP  ATP+KLA
 S66385 gb|CREB-binding protein [mice, brain, mRNA Partial, 7326 nt]. [S66385] KLA 1.00 .98 1.08 .98 1.04 1.07 1.08
ATP .99 .98 .99 1.09 1.13 1.08 1.05
KLA/ATP 1.06 1.00 1.05 1.03 1.02 1.14 1.11
Crk
KLA  ATP  ATP+KLA
 NM_133656 v-crk sarcoma virus CT10 oncogene homolog (avian) (Crk), mRNA [NM_133656] KLA 1.29 1.32 1.41 1.38 1.75 1.59 1.52
ATP 1.08 1.17 1.01 .93 1.27 2.11 1.70
KLA/ATP 1.37 1.49 1.14 1.09 1.21 1.69 2.32
Crkl
KLA  ATP  ATP+KLA
 NM_007764 v-crk sarcoma virus CT10 oncogene homolog (avian)-like (Crkl), mRNA [NM_007764] KLA 1.85 1.97 2.08 1.73 1.66 1.64 1.36
ATP .97 .94 .78 .74 1.46 1.89 1.46
KLA/ATP 1.92 1.88 1.18 1.44 1.67 2.65 2.72
Csf1r
KLA  ATP  ATP+KLA
 NM_001037859 colony stimulating factor 1 receptor (Csf1r), mRNA [NM_001037859] KLA .76 .81 .88 .67 .74 .78 .90
ATP 1.10 1.22 .88 1.10 .87 .78 1.28
KLA/ATP .97 .87 .63 .83 .51 .66 1.18
Csf2ra
KLA  ATP  ATP+KLA
 NM_009970 colony stimulating factor 2 receptor, alpha, low-affinity (granulocyte-macrophage) (Csf2ra), mRNA [NM_009970] KLA 1.10 1.06 1.03 1.13 1.24 1.35 1.09
ATP .89 .87 .95 .81 .86 1.10 1.06
KLA/ATP .94 .98 1.22 1.02 1.18 1.11 1.22
Csf3r
KLA  ATP  ATP+KLA
 NM_007782 colony stimulating factor 3 receptor (granulocyte) (Csf3r), mRNA [NM_007782] KLA 4.44 4.65 6.62 6.79 9.58 9.08 7.39
ATP 1.27 1.26 1.06 1.43 1.13 1.07 1.28
KLA/ATP 5.07 5.53 4.84 7.70 3.86 3.49 7.22
Ctbp1
KLA  ATP  ATP+KLA
 NM_013502 C-terminal binding protein 1 (Ctbp1), mRNA [NM_013502] KLA .77 .77 .71 .65 .67 .65 .95
ATP .89 .84 .42 .45 .45 .71 .80
KLA/ATP .73 .65 .30 .34 .34 .64 .61
Ctbp2
KLA  ATP  ATP+KLA
 NM_009980 C-terminal binding protein 2 (Ctbp2), mRNA [NM_009980] KLA .59 .57 .49 .44 .44 .60 .85
ATP .91 .87 .75 .79 .72 .89 .96
KLA/ATP .60 .50 .41 .45 .54 .63 .71
Ctnna1
KLA  ATP  ATP+KLA
 AK008121 adult male small intestine cDNA, RIKEN full-length enriched library, clone:2010005H04 product:unclassifiable, full insert sequence. [AK008121] KLA .82 .76 .72 .81 .94 .74 .80
ATP 1.08 1.01 .51 .57 2.45 1.25 .95
KLA/ATP .91 .82 .76 .58 1.58 1.01 .92
Ctnna1
KLA  ATP  ATP+KLA
 NM_009818 catenin (cadherin associated protein), alpha 1 (Ctnna1), mRNA [NM_009818] KLA .97 .91 1.06 .84 .75 .52 .56
ATP 1.09 1.14 1.00 .86 .80 .98 .83
KLA/ATP 1.02 1.07 .90 .80 .66 .59 .57
Ctnna2
KLA  ATP  ATP+KLA
 AK035033 12 days embryo embryonic body between diaphragm region and neck cDNA, RIKEN full-length enriched library, clone:9430076K22 product:hypothetical Vinculin and alpha-catenin containing protein, full insert sequence [AK035033] KLA 1.05 1.11 1.12 1.05 1.02 1.04 1.19
ATP .99 .97 1.00 1.05 1.02 1.05 1.03
KLA/ATP 1.11 1.06 1.01 1.12 1.06 1.02 1.03
Ctnna3
KLA  ATP  ATP+KLA
 AK029664 adult male testis cDNA, RIKEN full-length enriched library, clone:4930438F12 product:unclassifiable, full insert sequence. [AK029664] KLA 1.03 1.06 .99 1.05 .95 1.01 1.04
ATP 1.03 1.05 1.02 1.04 .99 1.03 1.05
KLA/ATP 1.01 1.00 .99 1.01 1.00 .98 1.05
Ctnna3
KLA  ATP  ATP+KLA
 NM_177612 catenin (cadherin associated protein), alpha 3 (Ctnna3), mRNA [NM_177612] KLA 1.01 1.06 .98 1.04 1.03 1.04 1.07
ATP .96 1.02 .94 1.11 1.02 1.09 .91
KLA/ATP 1.01 .94 .94 1.10 1.10 1.04 1.04
Ctnnb1
KLA  ATP  ATP+KLA
 AK020013 adult male thymus cDNA, RIKEN full-length enriched library, clone:5830416C23 product:catenin beta, full insert sequence. [AK020013] KLA 1.06 1.15 1.00 1.06 1.27 1.14 1.03
ATP .85 .57 1.74 3.36 4.13 2.19 1.55
KLA/ATP 1.12 .87 2.47 3.61 3.79 2.21 2.06
Ctnnb1
KLA  ATP  ATP+KLA
 NM_007614 catenin (cadherin associated protein), beta 1 (Ctnnb1), mRNA [NM_007614] KLA 1.02 1.07 1.13 1.03 1.04 .93 .96
ATP 1.12 1.14 .75 .77 .73 .72 1.52
KLA/ATP 1.18 1.17 .77 .85 .60 .59 1.35
Cul2
KLA  ATP  ATP+KLA
 NM_029402 cullin 2 (Cul2), mRNA [NM_029402] KLA 2.33 2.37 2.43 1.90 1.34 1.10 1.09
ATP .98 .92 .98 .78 .73 .90 .76
KLA/ATP 2.27 2.19 1.86 1.53 1.07 .95 .81
Cycs
KLA  ATP  ATP+KLA
 NM_007808 cytochrome c, somatic (Cycs), nuclear gene encoding mitochondrial protein, mRNA [NM_007808] KLA 2.20 2.21 2.35 2.69 2.62 3.22 2.14
ATP .87 .89 1.31 1.05 1.06 1.20 1.26
KLA/ATP 1.88 2.04 2.86 2.26 2.57 2.45 2.03
Cyct
KLA  ATP  ATP+KLA
 NM_009989 cytochrome c, testis (Cyct), mRNA [NM_009989] KLA .93 1.01 1.00 .99 1.02 1.03 .96
ATP 1.01 .91 1.01 .99 .98 .95 .95
KLA/ATP 1.10 .96 .89 .89 1.10 1.05 .97
Dapk1
KLA  ATP  ATP+KLA
 AK009701 adult male tongue cDNA, RIKEN full-length enriched library, clone:2310039H24 product:death associated protein kinase 1, full insert sequence. [AK009701] KLA .90 .84 .84 .88 .84 .88 .93
ATP .97 1.00 1.08 1.03 .93 1.02 1.13
KLA/ATP .92 .84 .75 .96 .83 .91 .92
Dapk1
KLA  ATP  ATP+KLA
 NM_029653 death associated protein kinase 1 (Dapk1), transcript variant 1, mRNA [NM_029653] KLA .35 .33 .35 .35 .42 .62 .59
ATP 1.00 .91 .75 .95 .80 .97 .64
KLA/ATP .33 .31 .35 .36 .44 .77 .69
Dapk2
KLA  ATP  ATP+KLA
 NM_010019 death-associated kinase 2 (Dapk2), mRNA [NM_010019] KLA 1.07 1.09 1.11 1.10 1.10 1.03 1.06
ATP 1.02 .99 1.08 .99 1.01 .99 1.50
KLA/ATP 1.03 1.12 1.18 1.05 .94 1.04 1.36
Dapk3
KLA  ATP  ATP+KLA
 NM_007828 death-associated kinase 3 (Dapk3), mRNA [NM_007828] KLA 1.12 1.19 1.11 1.19 1.41 1.25 1.53
ATP 1.12 1.29 .95 1.74 1.16 1.03 1.66
KLA/ATP 1.27 1.42 .96 1.55 .96 1.30 2.11
Dcc
KLA  ATP  ATP+KLA
 X85788 gb|M.musculus mRNA for DCC tumour suppressor. [X85788] KLA 1.01 1.04 .94 1.03 .98 1.05 1.02
ATP 1.04 1.04 1.08 1.03 .99 1.05 1.04
KLA/ATP 1.01 1.01 .98 1.05 1.00 .86 .97
Dvl1
KLA  ATP  ATP+KLA
 NM_010091 dishevelled, dsh homolog 1 (Drosophila) (Dvl1), mRNA [NM_010091] KLA .93 .91 .86 .74 .70 .80 1.05
ATP 1.01 1.01 .91 .91 .98 1.10 1.02
KLA/ATP 1.00 .93 .79 .82 .81 .85 1.06
Dvl2
KLA  ATP  ATP+KLA
 NM_007888 dishevelled 2, dsh homolog (Drosophila) (Dvl2), mRNA [NM_007888] KLA .49 .52 .48 .53 .52 .67 .75
ATP 1.08 1.08 .76 .93 1.47 .89 1.20
KLA/ATP .57 .47 .40 .61 1.37 .91 .92
Dvl3
KLA  ATP  ATP+KLA
 NM_007889 dishevelled 3, dsh homolog (Drosophila) (Dvl3), mRNA [NM_007889] KLA 1.08 1.09 1.05 1.18 1.11 1.10 1.11
ATP 1.00 1.01 1.05 1.05 .99 1.10 1.15
KLA/ATP 1.12 1.07 1.09 1.09 1.06 1.15 1.09
E2f1
KLA  ATP  ATP+KLA
 NM_007891 E2F transcription factor 1 (E2f1), mRNA [NM_007891] KLA .41 .44 .42 .41 .48 .77 .90
ATP 1.01 1.09 1.04 1.13 .83 .53 .84
KLA/ATP .44 .44 .52 .50 .49 .46 .85
E2f2
KLA  ATP  ATP+KLA
 NM_177733 E2F transcription factor 2 (E2f2), mRNA [NM_177733] KLA .13 .13 .14 .20 .19 .19 .18
ATP 1.08 .92 1.01 .85 .65 .38 .38
KLA/ATP .13 .13 .21 .20 .32 .24 .26
E2f3
KLA  ATP  ATP+KLA
 AK085296 0 day neonate kidney cDNA, RIKEN full-length enriched library, clone:D630007K21 product:E2F transcription factor 3, full insert sequence. [AK085296] KLA .98 .97 1.02 1.00 .99 .99 .99
ATP .97 1.06 1.03 .98 1.01 .99 1.00
KLA/ATP 1.12 1.14 1.03 .99 .96 .93 .96
E2f3
KLA  ATP  ATP+KLA
 NM_010093 E2F transcription factor 3 (E2f3), mRNA [NM_010093] KLA 1.11 1.09 1.13 1.21 1.47 1.62 1.65
ATP .97 .98 1.08 1.15 1.45 1.73 1.80
KLA/ATP 1.21 1.13 1.07 1.20 1.45 1.56 1.62
Egf
KLA  ATP  ATP+KLA
 NM_010113 epidermal growth factor (Egf), mRNA [NM_010113] KLA .89 .90 .81 .83 .83 .86 .92
ATP 1.03 1.03 .95 .84 .67 .79 .88
KLA/ATP .86 .86 .77 .77 .69 .78 .83
Egfr
KLA  ATP  ATP+KLA
 NM_007912 epidermal growth factor receptor (Egfr), transcript variant 2, mRNA [NM_007912] KLA 1.10 1.07 1.14 1.11 1.08 1.03 .90
ATP .99 1.00 1.04 .98 .97 1.15 1.14
KLA/ATP 1.07 1.10 1.16 1.08 1.01 .97 .94
Egfr
KLA  ATP  ATP+KLA
 NM_207655 epidermal growth factor receptor (Egfr), transcript variant 1, mRNA [NM_207655] KLA 1.57 1.44 1.47 1.31 .96 .92 .76
ATP .97 .93 1.10 1.00 1.41 2.97 .86
KLA/ATP 1.44 1.50 1.61 1.30 1.14 1.21 .82
Egln1
KLA  ATP  ATP+KLA
 NM_053207 EGL nine homolog 1 (C. elegans) (Egln1), mRNA [NM_053207] KLA .60 .60 .62 .54 .46 .48 .73
ATP 1.04 1.10 .94 1.00 .78 .84 .65
KLA/ATP .65 .64 .56 .53 .49 .47 .41
Egln2
KLA  ATP  ATP+KLA
 NM_053208 EGL nine homolog 2 (C. elegans) (Egln2), mRNA [NM_053208] KLA 1.12 1.22 1.40 1.55 1.86 1.39 1.19
ATP .94 .82 .61 .52 .74 1.26 1.29
KLA/ATP 1.11 1.04 .87 .73 1.28 1.53 1.54
Egln3
KLA  ATP  ATP+KLA
 NM_028133 EGL nine homolog 3 (C. elegans) (Egln3), mRNA [NM_028133] KLA .90 .90 .76 .73 .69 .83 1.38
ATP .96 1.03 .88 1.21 1.49 2.94 .90
KLA/ATP .88 .96 .78 .90 .98 1.18 1.15
Ep300
KLA  ATP  ATP+KLA
 AK042627 7 days neonate cerebellum cDNA, RIKEN full-length enriched library, clone:A730011L11 product:P300 TRANSCRIPTION COACTIVATOR (FRAGMENT) homolog [Mus sp], full insert sequence. [AK042627] KLA 1.02 .95 .92 1.04 1.01 1.00 1.05
ATP 1.06 .89 .88 .89 1.00 .90 1.07
KLA/ATP 1.10 1.02 .87 .91 1.04 .97 .98
Ep300
KLA  ATP  ATP+KLA
 NM_177821 E1A binding protein p300 (Ep300), mRNA [NM_177821] KLA 1.61 1.26 1.57 1.38 1.78 1.41 1.40
ATP 1.34 1.60 1.11 1.08 1.16 1.05 1.15
KLA/ATP 1.86 1.94 1.18 1.56 1.71 1.42 2.05
Epas1
KLA  ATP  ATP+KLA
 AK087208 0 day neonate lung cDNA, RIKEN full-length enriched library, clone:E030034H04 product:endothelial PAS domain protein 1, full insert sequence. [AK087208] KLA .92 .91 .87 .93 1.01 .85 .83
ATP 1.02 1.12 1.03 1.29 1.23 1.12 .88
KLA/ATP .85 .85 1.05 1.23 1.14 .93 .81
Epas1
KLA  ATP  ATP+KLA
 NM_010137 endothelial PAS domain protein 1 (Epas1), mRNA [NM_010137] KLA 1.12 1.03 1.19 1.00 1.00 1.02 .99
ATP 1.09 1.03 .96 .91 .95 .94 .85
KLA/ATP 1.09 1.21 1.09 .97 1.00 .93 .95
Erbb2
KLA  ATP  ATP+KLA
 NM_001003817 v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog (avian) (Erbb2), mRNA [NM_001003817] KLA 1.01 1.00 .98 1.01 .98 .99 .97
ATP .99 1.00 1.00 1.00 .96 .98 .99
KLA/ATP 1.00 1.01 1.01 1.02 .96 .98 .97
Evi1
KLA  ATP  ATP+KLA
 BC076620 ecotropic viral integration site 1, mRNA (cDNA clone IMAGE:30645345), partial cds [BC076620] KLA 1.04 .98 1.05 .96 1.09 1.04 .92
ATP .94 .96 1.11 1.00 1.03 1.08 1.14
KLA/ATP 1.00 .92 1.02 1.12 1.06 1.00 1.08
Evi1
KLA  ATP  ATP+KLA
 NM_007963 ecotropic viral integration site 1 (Evi1), mRNA [NM_007963] KLA .93 .99 1.04 1.02 1.05 1.11 1.10
ATP .96 .96 .98 1.03 1.03 .85 1.02
KLA/ATP 1.04 .95 .97 1.01 1.10 1.09 .99
Fadd
KLA  ATP  ATP+KLA
 NM_010175 Fas (TNFRSF6)-associated via death domain (Fadd), mRNA [NM_010175] KLA .54 .54 .59 .64 .80 .97 1.16
ATP 1.05 1.09 1.03 1.65 1.18 .78 1.61
KLA/ATP .56 .56 .53 .78 .78 .82 1.34
Fas
KLA  ATP  ATP+KLA
 AK086933 0 day neonate lung cDNA, RIKEN full-length enriched library, clone:E030012O08 product:tumor necrosis factor receptor superfamily, member 6, full insert sequence. [AK086933] KLA 6.31 6.56 6.33 6.70 4.93 3.74 2.48
ATP .95 1.04 1.33 1.55 1.85 6.00 2.77
KLA/ATP 5.67 7.16 7.71 7.73 6.02 5.79 7.85
Fas
KLA  ATP  ATP+KLA
 NM_007987 Fas (TNF receptor superfamily member 6) (Fas), mRNA [NM_007987] KLA 17.08 17.45 19.08 17.38 13.33 6.78 4.46
ATP .98 .96 1.64 3.05 5.58 12.91 1.89
KLA/ATP 16.57 17.25 26.06 23.57 22.03 16.74 13.29
Fasl
KLA  ATP  ATP+KLA
 NM_010177 Fas ligand (TNF superfamily, member 6) (Fasl), mRNA [NM_010177] KLA 1.03 1.01 1.03 1.02 1.01 1.01 1.00
ATP 1.00 .99 1.04 1.21 1.18 1.20 1.01
KLA/ATP 1.00 1.02 1.07 1.16 1.18 1.23 1.00
Fgf1
KLA  ATP  ATP+KLA
 NM_010197 fibroblast growth factor 1 (Fgf1), mRNA [NM_010197] KLA 1.07 .99 .99 1.00 1.03 .97 .99
ATP 1.01 1.03 1.01 .95 .95 .98 .88
KLA/ATP 1.03 .99 .97 .99 .98 .94 1.01
Fgf10
KLA  ATP  ATP+KLA
 NM_008002 fibroblast growth factor 10 (Fgf10), mRNA [NM_008002] KLA .99 .98 1.02 1.00 1.02 1.02 1.02
ATP 1.03 1.02 1.00 1.00 1.00 .99 .99
KLA/ATP 1.01 1.00 1.04 .99 1.00 1.02 1.01
Fgf11
KLA  ATP  ATP+KLA
 BC066859 fibroblast growth factor 11, mRNA (cDNA clone MGC:76712 IMAGE:30101881), complete cds [BC066859] KLA .64 .61 .55 .58 .51 .48 .77
ATP 1.00 .96 .78 .78 .63 .44 .48
KLA/ATP .64 .63 .59 .56 .54 .42 .40
Fgf11
KLA  ATP  ATP+KLA
 NM_010198 fibroblast growth factor 11 (Fgf11), mRNA [NM_010198] KLA .99 1.02 1.05 1.04 1.01 1.03 1.07
ATP .95 1.02 1.02 1.07 .98 1.01 1.07
KLA/ATP 1.01 1.01 1.08 .96 .97 .95 1.01
Fgf12
KLA  ATP  ATP+KLA
 NM_183064 fibroblast growth factor 12 (Fgf12), transcript variant 1, mRNA [NM_183064] KLA .96 .97 1.05 .99 .97 1.01 1.01
ATP .93 .97 .97 .97 .99 .95 1.00
KLA/ATP 1.02 1.05 1.10 1.02 .95 1.01 .95
Fgf13
KLA  ATP  ATP+KLA
 NM_010200 fibroblast growth factor 13 (Fgf13), mRNA [NM_010200] KLA .91 .92 .93 .84 .77 .66 .75
ATP 1.09 1.14 1.03 1.11 1.06 .68 .78
KLA/ATP .98 1.02 .86 .90 .78 .70 .79
Fgf14
KLA  ATP  ATP+KLA
 NM_010201 fibroblast growth factor 14 (Fgf14), transcript variant 1, mRNA [NM_010201] KLA 1.04 1.05 1.02 1.04 1.03 1.05 1.03
ATP .99 1.08 1.04 1.00 .99 .98 1.04
KLA/ATP 1.00 1.00 1.08 1.00 1.04 1.01 1.03
Fgf14
KLA  ATP  ATP+KLA
 NM_207667 fibroblast growth factor 14 (Fgf14), transcript variant 2, mRNA [NM_207667] KLA 1.04 1.01 .98 .93 .96 .96 .97
ATP 1.04 1.10 .94 .87 1.03 .99 .96
KLA/ATP .86 .94 1.03 .89 1.00 .90 1.03
Fgf15
KLA  ATP  ATP+KLA
 NM_008003 fibroblast growth factor 15 (Fgf15), mRNA [NM_008003] KLA 1.00 1.00 .95 .98 .92 .96 1.01
ATP .99 1.01 .98 .98 .93 .95 .97
KLA/ATP .98 1.01 1.02 1.03 .97 .97 1.00
Fgf16
KLA  ATP  ATP+KLA
 NM_030614 fibroblast growth factor 16 (Fgf16), mRNA [NM_030614] KLA 1.00 .97 .99 1.02 1.04 .97 .97
ATP 1.02 .99 .99 1.02 1.12 1.01 1.02
KLA/ATP 1.06 1.02 .99 1.01 1.00 1.10 1.03
Fgf17
KLA  ATP  ATP+KLA
 NM_008004 fibroblast growth factor 17 (Fgf17), mRNA [NM_008004] KLA .97 1.03 .98 1.00 .97 .97 .86
ATP .99 .96 .99 .90 1.02 1.01 1.01
KLA/ATP .99 .91 1.08 .99 .99 .98 .99
Fgf18
KLA  ATP  ATP+KLA
 NM_008005 fibroblast growth factor 18 (Fgf18), mRNA [NM_008005] KLA 1.17 1.18 1.16 1.12 1.03 1.13 1.04
ATP .96 .98 2.47 12.57 2.76 1.56 1.03
KLA/ATP 1.01 1.15 2.33 10.13 2.80 1.79 1.02
Fgf2
KLA  ATP  ATP+KLA
 NM_008006 fibroblast growth factor 2 (Fgf2), mRNA [NM_008006] KLA 1.02 1.01 1.00 1.03 1.01 1.02 1.01
ATP .99 1.01 1.00 1.02 1.01 1.01 1.00
KLA/ATP 1.00 1.01 .98 1.01 1.02 1.03 1.01
Fgf20
KLA  ATP  ATP+KLA
 NM_030610 fibroblast growth factor 20 (Fgf20), mRNA [NM_030610] KLA .97 1.08 .99 1.00 .97 1.00 .97
ATP 1.03 .95 .97 1.05 .98 .97 1.00
KLA/ATP .99 .99 1.06 1.04 1.02 .92 .96
Fgf21
KLA  ATP  ATP+KLA
 NM_020013 fibroblast growth factor 21 (Fgf21), mRNA [NM_020013] KLA 1.02 1.03 .87 1.04 1.00 1.01 1.00
ATP 1.04 .97 1.00 1.02 .96 1.05 1.02
KLA/ATP 1.08 1.00 1.00 1.00 1.03 1.02 .99
Fgf22
KLA  ATP  ATP+KLA
 AK008922 adult male stomach cDNA, RIKEN full-length enriched library, clone:2210414E06 product:FIBROBLAST GROWTH FACTOR-22 PRECURSOR (FGF-22) homolog [Mus musculus], full insert sequence [AK008922] KLA .90 .94 .95 1.04 1.03 .94 .97
ATP 1.04 1.01 .98 .93 .93 .95 .88
KLA/ATP .98 .97 .97 1.01 .95 .92 .95
Fgf22
KLA  ATP  ATP+KLA
 NM_023304 fibroblast growth factor 22 (Fgf22), mRNA [NM_023304] KLA .99 .94 1.01 .95 .97 .89 .99
ATP 1.00 .95 1.00 .96 .97 .93 .98
KLA/ATP .91 1.00 1.01 .92 .95 .98 .97
Fgf23
KLA  ATP  ATP+KLA
 NM_022657 fibroblast growth factor 23 (Fgf23), mRNA [NM_022657] KLA 1.32 1.39 1.27 1.22 1.07 1.03 1.14
ATP .95 1.00 1.05 1.07 1.05 1.02 .96
KLA/ATP 1.32 1.39 1.37 1.22 1.01 1.00 .90
Fgf3
KLA  ATP  ATP+KLA
 NM_008007 fibroblast growth factor 3 (Fgf3), mRNA [NM_008007] KLA 1.03 1.05 1.00 .97 1.01 .98 .97
ATP 1.01 1.00 .97 1.03 .98 1.03 .97
KLA/ATP .98 1.00 1.01 1.03 1.03 1.00 .99
Fgf5
KLA  ATP  ATP+KLA
 NM_010203 fibroblast growth factor 5 (Fgf5), mRNA [NM_010203] KLA 1.02 1.02 1.00 1.03 .97 1.05 .99
ATP 1.02 1.00 1.03 .97 .99 .97 1.04
KLA/ATP 1.05 .92 1.01 1.00 1.11 .96 .97
Fgf6
KLA  ATP  ATP+KLA
 M92416 fibroblast growth factor (Fgf6) mRNA, 3 end [M92416] KLA 1.09 1.07 1.00 1.06 .97 1.01 .96
ATP 1.02 1.02 1.06 1.02 .93 .99 .98
KLA/ATP 1.04 .99 1.00 .99 1.00 1.00 1.03
Fgf6
KLA  ATP  ATP+KLA
 NM_010204 fibroblast growth factor 6 (Fgf6), mRNA [NM_010204] KLA 1.00 .96 1.06 .96 .96 1.00 .91
ATP .94 1.00 .89 .95 1.01 .92 1.00
KLA/ATP .99 1.06 1.06 .86 1.00 .95 1.00
Fgf7
KLA  ATP  ATP+KLA
 NM_008008 fibroblast growth factor 7 (Fgf7), mRNA [NM_008008] KLA 1.02 1.02 1.02 1.03 1.05 1.11 1.04
ATP 1.00 1.01 1.11 1.15 1.05 1.04 1.06
KLA/ATP .99 .96 .83 1.10 1.15 1.26 1.21
Fgf8
KLA  ATP  ATP+KLA
 BC048734 fibroblast growth factor 8, mRNA (cDNA clone MGC:59627 IMAGE:6513131), complete cds [BC048734] KLA .96 .95 1.03 .96 1.06 .97 .96
ATP 1.08 .94 1.07 1.10 1.00 .93 1.06
KLA/ATP 1.03 1.02 1.04 .96 1.04 .94 .94
Fgf8
KLA  ATP  ATP+KLA
 NM_010205 fibroblast growth factor 8 (Fgf8), mRNA [NM_010205] KLA 1.00 1.00 1.03 1.04 1.04 1.07 1.09
ATP 1.01 1.01 1.11 1.14 1.11 1.09 1.05
KLA/ATP 1.00 1.04 1.14 1.18 1.15 1.09 1.04
Fgf9
KLA  ATP  ATP+KLA
 NM_013518 fibroblast growth factor 9 (Fgf9), mRNA [NM_013518] KLA 1.04 1.07 1.07 1.12 .97 .96 .91
ATP 1.02 1.08 .98 1.00 .94 .99 .92
KLA/ATP 1.04 1.03 1.03 1.00 .93 .93 .89
Fgfr1
KLA  ATP  ATP+KLA
 M28998 gb|Mouse basic fibroblast growth factor receptor (bFGF-R) mRNA, complete cds. [M28998] KLA .82 .79 .73 .66 .50 .55 .65
ATP 1.01 1.08 .86 .90 1.29 1.24 1.52
KLA/ATP .85 .82 .71 .71 .63 .80 .85
Fgfr1
KLA  ATP  ATP+KLA
 NM_010206 fibroblast growth factor receptor 1 (Fgfr1), transcript variant 1, mRNA [NM_010206] KLA .92 .86 .73 .82 .79 .85 .84
ATP 1.01 1.06 .92 .92 1.18 1.02 1.22
KLA/ATP .83 .83 .79 .76 .83 .83 .92
Fgfr2
KLA  ATP  ATP+KLA
 NM_010207 fibroblast growth factor receptor 2 (Fgfr2), transcript variant 1, mRNA [NM_010207] KLA 1.01 .98 1.00 1.01 .98 1.00 .99
ATP 1.00 1.03 1.05 1.03 1.01 1.01 1.00
KLA/ATP 1.00 1.01 1.04 1.01 .99 1.02 1.03
Fgfr3
KLA  ATP  ATP+KLA
 NM_008010 fibroblast growth factor receptor 3 (Fgfr3), mRNA [NM_008010] KLA 1.09 1.15 1.05 1.10 1.02 1.05 1.12
ATP 1.05 .94 .98 .87 .91 .95 .92
KLA/ATP 1.13 1.11 1.10 .91 .92 .93 .92
Fh1
KLA  ATP  ATP+KLA
 NM_010209 fumarate hydratase 1 (Fh1), mRNA [NM_010209] KLA 1.00 .88 .79 .83 .55 .36 .39
ATP 1.05 1.05 1.08 .98 .89 .49 .45
KLA/ATP .91 .95 1.06 .92 .72 .41 .18
Figf
KLA  ATP  ATP+KLA
 NM_010216 c-fos induced growth factor (Figf), mRNA [NM_010216] KLA .92 .95 .93 .87 .82 .87 .77
ATP 1.03 1.04 1.06 .90 1.13 2.02 .78
KLA/ATP .92 .94 .97 .85 .97 1.10 .92
Flt3
KLA  ATP  ATP+KLA
 NM_010229 FMS-like tyrosine kinase 3 (Flt3), mRNA [NM_010229] KLA .99 1.01 1.05 1.01 1.05 1.01 1.01
ATP .92 .98 1.09 1.12 1.00 1.02 1.03
KLA/ATP 1.04 .99 .89 1.01 .99 .94 1.05
Flt3l
KLA  ATP  ATP+KLA
 NM_013520 FMS-like tyrosine kinase 3 ligand (Flt3l), mRNA [NM_013520] KLA 1.08 1.12 1.37 1.32 1.68 1.86 1.67
ATP 1.08 1.03 1.05 1.22 .90 .71 1.26
KLA/ATP 1.12 1.16 1.20 1.22 1.09 .91 1.29
Fn1
KLA  ATP  ATP+KLA
 NM_010233 fibronectin 1 (Fn1), mRNA [NM_010233] KLA 1.23 1.30 1.38 1.12 1.16 1.00 .78
ATP 1.02 1.19 1.25 1.56 1.33 1.05 .95
KLA/ATP 1.36 1.51 1.34 1.70 1.20 1.06 .93
Fos
KLA  ATP  ATP+KLA
 NM_010234 FBJ osteosarcoma oncogene (Fos), mRNA [NM_010234] KLA .42 .33 .64 .61 .71 .85 .71
ATP 3.48 5.46 23.78 25.22 1.71 2.36 1.50
KLA/ATP .90 1.74 5.97 8.62 1.28 2.42 4.52
Foxo1
KLA  ATP  ATP+KLA
 NM_019739 forkhead box O1 (Foxo1), mRNA [NM_019739] KLA .60 .55 .60 .58 .49 .60 .71
ATP .96 1.03 1.08 1.03 2.49 1.70 .98
KLA/ATP .56 .58 .67 .83 1.47 1.57 .97
Frap1
KLA  ATP  ATP+KLA
 NM_020009 FK506 binding protein 12-rapamycin associated protein 1 (Frap1), mRNA [NM_020009] KLA 1.37 1.32 1.46 1.57 1.83 1.29 1.28
ATP 1.12 1.07 .95 .91 .80 .77 1.03
KLA/ATP 1.45 1.51 1.50 1.11 .89 .87 1.01
Fzd1
KLA  ATP  ATP+KLA
 NM_021457 frizzled homolog 1 (Drosophila) (Fzd1), mRNA [NM_021457] KLA 15.53 16.47 14.36 11.40 6.80 2.73 2.49
ATP 1.01 1.02 1.39 2.05 6.43 10.47 1.41
KLA/ATP 12.71 14.30 14.99 14.06 9.72 9.90 8.10
Fzd10
KLA  ATP  ATP+KLA
 NM_175284 frizzled homolog 10 (Drosophila) (Fzd10), mRNA [NM_175284] KLA .99 .98 .99 1.03 1.03 1.02 .99
ATP .98 .98 .97 1.03 1.05 1.00 .96
KLA/ATP .96 .98 1.08 1.02 1.04 1.02 1.00
Fzd2
KLA  ATP  ATP+KLA
 NM_020510 frizzled homolog 2 (Drosophila) (Fzd2), mRNA [NM_020510] KLA .97 1.01 1.01 1.02 1.00 .96 .97
ATP 1.01 1.02 1.03 1.02 .97 1.03 .93
KLA/ATP 1.04 .98 .99 1.03 .99 1.03 .98
Fzd3
KLA  ATP  ATP+KLA
 NM_021458 frizzled homolog 3 (Drosophila) (Fzd3), mRNA [NM_021458] KLA 1.00 1.00 .99 1.04 1.02 1.06 1.07
ATP 1.00 1.00 .95 1.04 1.04 1.01 1.05
KLA/ATP .98 1.05 1.06 .99 1.02 1.00 1.03
Fzd4
KLA  ATP  ATP+KLA
 NM_008055 frizzled homolog 4 (Drosophila) (Fzd4), mRNA [NM_008055] KLA .96 .88 .91 .92 .82 .89 .84
ATP .97 .98 1.05 1.02 .93 .90 .96
KLA/ATP .82 .86 .97 .92 .88 .91 .92
Fzd5
KLA  ATP  ATP+KLA
 NM_022721 frizzled homolog 5 (Drosophila) (Fzd5), transcript variant 1, mRNA [NM_022721] KLA 1.63 1.69 1.56 1.23 .91 1.01 .92
ATP 1.03 1.32 4.46 9.23 7.72 2.14 1.11
KLA/ATP 1.63 1.92 4.20 8.67 8.29 3.07 1.12
Fzd6
KLA  ATP  ATP+KLA
 NM_008056 frizzled homolog 6 (Drosophila) (Fzd6), mRNA [NM_008056] KLA .97 1.01 .96 .90 .87 .94 .98
ATP .98 .97 .98 .94 .95 1.09 .96
KLA/ATP .97 1.02 .94 .92 .90 1.02 1.00
Fzd7
KLA  ATP  ATP+KLA
 NM_008057 frizzled homolog 7 (Drosophila) (Fzd7), mRNA [NM_008057] KLA 1.50 1.68 1.53 1.31 1.13 1.00 .94
ATP 1.04 1.12 1.60 3.45 2.56 1.72 1.02
KLA/ATP 1.89 1.92 1.96 4.61 3.75 3.38 1.88
Fzd8
KLA  ATP  ATP+KLA
 AK034561 12 days embryo embryonic body between diaphragm region and neck cDNA, RIKEN full-length enriched library, clone:9430006K02 product:inferred: transmembrane receptor {Mus musculus}; frizzled homolog 8 (Drosophila) homolog {GNF expression}, KLA 1.00 .98 1.05 .98 .96 1.03 .94
ATP 1.00 .92 1.06 1.05 1.02 1.01 .98
KLA/ATP .99 1.06 .99 .94 .95 .99 1.03
Fzd8
KLA  ATP  ATP+KLA
 NM_008058 frizzled homolog 8 (Drosophila) (Fzd8), mRNA [NM_008058] KLA 1.09 1.15 1.07 1.05 1.03 1.05 .98
ATP 1.05 1.08 2.01 3.38 2.89 1.20 1.03
KLA/ATP 1.04 1.17 1.65 2.57 2.62 1.40 1.04
Fzd9
KLA  ATP  ATP+KLA
 NM_010246 frizzled homolog 9 (Drosophila) (Fzd9), mRNA [NM_010246] KLA 1.03 1.10 1.12 .96 .98 1.00 .94
ATP 1.00 1.00 1.03 1.06 1.07 1.14 .98
KLA/ATP 1.10 1.07 1.03 .84 1.11 .96 .98
Gli1
KLA  ATP  ATP+KLA
 NM_010296 GLI-Kruppel family member GLI1 (Gli1), mRNA [NM_010296] KLA .97 .97 .97 .99 .97 .98 .96
ATP .98 1.01 .99 .98 .97 .96 .99
KLA/ATP .98 .98 1.01 .96 .98 .94 .95
Gli2
KLA  ATP  ATP+KLA
 NM_001081125 GLI-Kruppel family member GLI2 (Gli2), mRNA [NM_001081125] KLA 1.03 1.02 .99 1.04 1.02 1.04 1.00
ATP 1.01 1.00 1.04 1.06 1.02 .99 1.04
KLA/ATP .97 1.04 1.05 1.05 1.06 1.04 1.02
Gli3
KLA  ATP  ATP+KLA
 NM_008130 GLI-Kruppel family member GLI3 (Gli3), mRNA [NM_008130] KLA 1.01 1.01 1.01 1.01 1.01 .99 1.00
ATP 1.00 .99 1.03 1.00 1.01 1.01 1.02
KLA/ATP 1.02 1.01 1.02 .98 1.00 1.00 1.02
Grb2
KLA  ATP  ATP+KLA
 NM_008163 growth factor receptor bound protein 2 (Grb2), mRNA [NM_008163] KLA .92 .88 .90 1.27 1.43 1.22 1.00
ATP 1.02 .83 .51 .42 .92 .70 .57
KLA/ATP .84 .77 .61 .56 1.56 1.49 .52
Grb2
KLA  ATP  ATP+KLA
 U07617 Grb2 adaptor protein (grb2) mRNA, complete cds. [U07617] KLA .83 .80 .95 1.13 1.38 1.36 1.06
ATP .84 .74 .51 .41 .82 .74 .59
KLA/ATP .77 .70 .57 .54 1.49 1.39 .53
Gsk3b
KLA  ATP  ATP+KLA
 NM_019827 glycogen synthase kinase 3 beta (Gsk3b), mRNA [NM_019827] KLA 1.06 1.03 1.11 1.01 1.26 1.28 1.26
ATP 1.18 1.27 1.15 2.07 2.37 2.32 1.67
KLA/ATP 1.15 1.21 .98 1.50 1.67 2.50 2.99
Hdac1
KLA  ATP  ATP+KLA
 U80780 putative histone deacetylase (HD1) mRNA, partial cds [U80780] KLA 2.59 2.39 2.48 2.74 3.36 2.56 1.22
ATP 1.13 1.26 1.18 1.08 .85 1.29 1.15
KLA/ATP 2.15 2.27 2.64 2.57 1.78 1.89 2.31
Hdac2
KLA  ATP  ATP+KLA
 AK051753 12 days embryo spinal ganglion cDNA, RIKEN full-length enriched library, clone:D130072G11 product:histone deacetylase 2, full insert sequence [AK051753] KLA .97 .97 .90 .96 1.02 .93 .96
ATP 1.02 1.03 .98 .96 .96 .90 1.05
KLA/ATP 1.00 .96 .87 .99 .92 1.00 .95
Hdac2
KLA  ATP  ATP+KLA
 NM_008229 histone deacetylase 2 (Hdac2), mRNA [NM_008229] KLA 1.27 1.35 1.33 1.18 1.03 .75 1.10
ATP .95 1.05 .79 .96 .82 .85 .81
KLA/ATP 1.28 1.43 .93 1.10 .82 .73 .60
Hgf
KLA  ATP  ATP+KLA
 AK033274 15 days embryo male testis cDNA, RIKEN full-length enriched library, clone:8030481P22 product:inferred: hepatocyte growth factor [AK033274] KLA 1.34 1.22 .96 .93 .82 .93 .87
ATP 1.64 2.45 3.30 1.89 .97 1.12 .90
KLA/ATP 1.49 2.50 3.96 1.88 1.07 1.00 .83
Hgf
KLA  ATP  ATP+KLA
 NM_010427 hepatocyte growth factor (Hgf), mRNA [NM_010427] KLA 1.11 1.18 1.30 1.20 1.08 .96 1.14
ATP 1.02 1.14 1.32 1.62 1.17 1.26 1.47
KLA/ATP 1.18 1.24 1.33 1.84 1.19 1.09 1.31
Hhip
KLA  ATP  ATP+KLA
 NM_020259 Hedgehog-interacting protein (Hhip), mRNA [NM_020259] KLA 1.03 1.00 .96 1.04 1.07 1.01 .98
ATP 1.00 .96 1.07 1.01 1.00 1.07 .98
KLA/ATP .99 1.00 1.06 1.02 1.09 1.09 1.04
Hif1a
KLA  ATP  ATP+KLA
 NM_010431 hypoxia inducible factor 1, alpha subunit (Hif1a), mRNA [NM_010431] KLA 2.52 2.50 2.52 1.78 1.87 1.39 1.96
ATP 1.16 1.37 1.11 1.44 2.11 4.46 1.97
KLA/ATP 2.76 2.92 1.75 2.60 2.39 4.75 5.37
Hras1
KLA  ATP  ATP+KLA
 NM_008284 Harvey rat sarcoma virus oncogene 1 (Hras1), mRNA [NM_008284] KLA .79 .82 .77 .82 .94 1.03 1.07
ATP 1.01 .95 .69 .83 .79 1.12 1.15
KLA/ATP .84 .77 .61 .65 .82 1.00 1.05
Hsp90aa1
KLA  ATP  ATP+KLA
 NM_010480 heat shock protein 90, alpha (cytosolic), class A member 1 (Hsp90aa1), mRNA [NM_010480] KLA .95 1.03 .90 .92 .80 .94 .99
ATP .96 .92 1.39 1.21 2.02 3.66 1.10
KLA/ATP .93 .92 1.32 1.01 1.85 2.21 1.20
Hsp90ab1
KLA  ATP  ATP+KLA
 NM_008302 heat shock protein 90kDa alpha (cytosolic), class B member 1 (Hsp90ab1), mRNA [NM_008302] KLA .93 1.02 .98 .82 .95 1.10 1.39
ATP 1.04 1.14 .92 1.32 1.19 1.02 .63
KLA/ATP 1.02 1.04 .80 1.12 .87 .86 .75
Hsp90b1
KLA  ATP  ATP+KLA
 NM_011631 heat shock protein 90, beta (Grp94), member 1 (Hsp90b1), mRNA [NM_011631] KLA .78 .83 .71 .69 .73 .69 .80
ATP 1.00 1.08 1.01 .94 .84 .84 .66
KLA/ATP .78 .82 .81 .73 .66 .68 .27
Igf1
KLA  ATP  ATP+KLA
 AK050118 adult male liver tumor cDNA, RIKEN full-length enriched library, clone:C730016P09 product:unclassifiable, full insert sequence. [AK050118] KLA .13 .14 .15 .16 .22 .34 .48
ATP 1.78 2.05 1.37 .72 .34 .41 .58
KLA/ATP .24 .45 .50 .24 .20 .26 .68
Igf1
KLA  ATP  ATP+KLA
 NM_010512 insulin-like growth factor 1 (Igf1), transcript variant 1, mRNA [NM_010512] KLA .84 .78 .76 .67 .54 .48 .59
ATP .97 .98 1.13 1.13 1.03 .88 .89
KLA/ATP .82 .81 .93 .86 .83 .65 .89
Igf1
KLA  ATP  ATP+KLA
 NM_184052 insulin-like growth factor 1 (Igf1), transcript variant 2, mRNA [NM_184052] KLA .77 .82 .76 .65 .60 .52 .69
ATP 1.01 1.07 .98 1.06 1.03 .78 .94
KLA/ATP .89 .86 .77 .80 .75 .65 .89
Igf1r
KLA  ATP  ATP+KLA
 NM_010513 insulin-like growth factor I receptor (Igf1r), mRNA [NM_010513] KLA 1.32 1.32 1.08 .91 .55 .48 .45
ATP 1.03 1.06 1.06 1.29 1.31 1.45 .47
KLA/ATP 1.30 1.37 1.11 1.00 .93 1.02 .45
Ikbkb
KLA  ATP  ATP+KLA
 NM_010546 inhibitor of kappaB kinase beta (Ikbkb), mRNA [NM_010546] KLA 1.88 2.10 2.14 1.83 1.73 1.31 1.19
ATP .81 .74 .55 .49 .59 1.05 .96
KLA/ATP 1.86 1.73 1.39 1.12 .89 1.17 1.24
Ikbkg
KLA  ATP  ATP+KLA
 AK042138 3 days neonate thymus cDNA, RIKEN full-length enriched library, clone:A630062P04 product:unclassifiable, full insert sequence. [AK042138] KLA .92 .87 .78 .78 .87 .88 .62
ATP .84 .71 .80 .50 1.15 2.33 .61
KLA/ATP .72 .69 .74 .48 1.06 1.97 .68
Ikbkg
KLA  ATP  ATP+KLA
 NM_010547 inhibitor of kappaB kinase gamma (Ikbkg), transcript variant 1, mRNA [NM_010547] KLA 1.51 1.63 1.74 1.83 1.83 1.73 1.72
ATP .80 .79 .82 .75 .66 2.58 2.37
KLA/ATP 1.43 1.42 1.17 1.04 .71 1.54 3.17
Ikbkg
KLA  ATP  ATP+KLA
 NM_178590 inhibitor of kappaB kinase gamma (Ikbkg), transcript variant 2, mRNA [NM_178590] KLA .84 .93 .86 .91 1.03 .89 .88
ATP 1.03 .98 .68 .56 .51 .93 .68
KLA/ATP .89 .81 .55 .52 .41 .67 .65
Il6
KLA  ATP  ATP+KLA
 NM_031168 interleukin 6 (Il6), mRNA [NM_031168] KLA 352.99 378.70 276.81 168.47 59.99 18.66 8.27
ATP 1.04 1.08 2.28 3.69 30.40 161.93 2.11
KLA/ATP 334.28 528.66 ###.## 935.86 302.45 355.36 99.65
Itga2
KLA  ATP  ATP+KLA
 NM_008396 integrin alpha 2 (Itga2), mRNA [NM_008396] KLA 1.03 1.00 .98 1.01 .97 .96 1.00
ATP 1.05 .99 .93 1.02 1.04 1.03 .97
KLA/ATP .98 1.06 1.03 1.00 1.00 1.01 1.01
Itga2b
KLA  ATP  ATP+KLA
 NM_010575 integrin alpha 2b (Itga2b), mRNA [NM_010575] KLA 1.01 1.00 .98 1.04 1.01 1.04 1.18
ATP 1.01 .98 .95 1.02 .96 1.13 1.08
KLA/ATP 1.04 1.02 1.02 .95 1.05 1.53 1.23
Itga3
KLA  ATP  ATP+KLA
 NM_013565 integrin alpha 3 (Itga3), mRNA [NM_013565] KLA 1.06 1.09 1.10 1.17 1.19 1.29 1.41
ATP .99 .99 1.05 1.12 1.20 1.25 1.33
KLA/ATP 1.08 1.14 1.15 1.27 1.28 1.20 1.39
Itga6
KLA  ATP  ATP+KLA
 BC024571 integrin alpha 6, mRNA (cDNA clone IMAGE:5036677). [BC024571] KLA .44 .44 .37 .28 .25 .29 .34
ATP .96 1.01 .90 .58 .35 .11 .22
KLA/ATP .44 .41 .34 .23 .15 .09 .08
Itga6
KLA  ATP  ATP+KLA
 NM_008397 integrin alpha 6 (Itga6), mRNA [NM_008397] KLA .57 .58 .51 .45 .43 .44 .47
ATP 1.05 1.12 .86 .90 .57 .27 .36
KLA/ATP .64 .67 .50 .57 .39 .29 .26
Itgav
KLA  ATP  ATP+KLA
 AK052514 13 days embryo lung cDNA, RIKEN full-length enriched library, clone:D430040G12 product:hypothetical protein, full insert sequence. [AK052514] KLA 1.04 .93 1.05 1.02 1.01 .93 1.03
ATP 1.05 1.04 1.13 1.12 1.12 .91 1.02
KLA/ATP 1.08 .97 1.02 .95 1.01 .96 1.05
Itgav
KLA  ATP  ATP+KLA
 AK171739 activated spleen cDNA, RIKEN full-length enriched library, clone:F830008B15 product:unclassifiable, full insert sequence. [AK171739] KLA 1.04 .97 1.06 .95 1.15 .89 1.11
ATP 1.41 1.54 1.64 2.24 2.74 1.24 1.18
KLA/ATP 1.09 1.07 1.03 1.01 1.72 1.24 1.10
Itgav
KLA  ATP  ATP+KLA
 NM_008402 integrin alpha V (Itgav), mRNA [NM_008402] KLA 4.00 3.99 3.28 2.24 1.57 .95 1.13
ATP 1.14 1.22 1.13 1.39 2.22 2.47 1.70
KLA/ATP 4.59 4.61 2.48 2.44 1.60 1.88 2.56
Itgb1
KLA  ATP  ATP+KLA
 NM_010578 integrin beta 1 (fibronectin receptor beta) (Itgb1), mRNA [NM_010578] KLA 1.05 1.09 1.13 .92 1.01 .93 .88
ATP 1.14 1.30 .92 1.07 1.04 .83 .70
KLA/ATP 1.26 1.30 .87 1.02 .66 .65 .62
Itgb1
KLA  ATP  ATP+KLA
 U37029 integrin beta1D mRNA, partial cds. [U37029] KLA .93 .95 .96 1.01 .97 1.01 .98
ATP 1.05 .99 .99 1.03 1.03 .97 .94
KLA/ATP .99 .98 1.04 .97 1.02 1.01 .99
Jak1
KLA  ATP  ATP+KLA
 AK029232 0 day neonate head cDNA, RIKEN full-length enriched library, clone:4831433J01 product:Janus kinase 1, full insert sequence. [AK029232] KLA 1.25 1.13 1.19 1.31 1.24 1.17 1.14
ATP 1.01 1.11 .96 1.38 1.06 1.26 1.05
KLA/ATP 1.19 1.29 1.27 1.59 1.18 1.38 1.24
Jak1
KLA  ATP  ATP+KLA
 NM_146145 Janus kinase 1 (Jak1), mRNA [NM_146145] KLA 1.71 1.75 1.79 1.81 1.72 1.37 1.21
ATP 1.03 1.01 .75 1.04 1.32 1.90 1.14
KLA/ATP 1.84 1.73 1.49 2.07 2.01 1.83 1.68
Jun
KLA  ATP  ATP+KLA
 NM_010591 Jun oncogene (Jun), mRNA [NM_010591] KLA 1.08 .96 1.09 1.09 .75 .88 .81
ATP 1.26 1.48 4.45 8.73 4.02 1.16 1.99
KLA/ATP 1.12 1.38 3.52 5.17 3.32 .49 1.42
Jup
KLA  ATP  ATP+KLA
 NM_010593 junction plakoglobin (Jup), mRNA [NM_010593] KLA .96 .98 .98 .88 .99 1.26 .77
ATP .99 1.08 .99 .99 .98 1.06 .82
KLA/ATP .96 .92 .92 .93 1.00 1.49 .80
Kit
KLA  ATP  ATP+KLA
 Y00864 gb|Mouse c-kit mRNA. [Y00864] KLA .88 .86 .83 .76 .75 .73 .87
ATP 1.06 1.07 1.03 1.04 3.95 1.93 1.25
KLA/ATP .87 .87 .89 .89 1.06 1.08 .91
Kitl
KLA  ATP  ATP+KLA
 NM_013598 kit ligand (Kitl), mRNA [NM_013598] KLA .49 .46 .43 .38 .23 .35 .46
ATP .89 .85 .79 .91 1.14 1.30 .86
KLA/ATP .48 .43 .49 .96 1.59 1.38 .95
Kras
KLA  ATP  ATP+KLA
 NM_021284 v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (Kras), mRNA [NM_021284] KLA .53 .49 .40 .42 .49 .95 1.05
ATP .98 1.01 1.16 1.17 1.39 1.29 1.74
KLA/ATP .50 .47 .50 .56 1.00 1.24 1.58
Lama1
KLA  ATP  ATP+KLA
 NM_008480 laminin, alpha 1 (Lama1), mRNA [NM_008480] KLA .99 1.04 .97 .96 1.01 .99 1.05
ATP 1.01 .99 .98 1.05 .99 1.09 .99
KLA/ATP 1.00 .97 .86 1.04 1.05 .99 1.00
Lama2
KLA  ATP  ATP+KLA
 AK046114 adult male corpora quadrigemina cDNA, RIKEN full-length enriched library, clone:B230342M05 product:laminin, alpha 2, full insert sequence. [AK046114] KLA 1.06 1.00 .95 1.10 1.04 .99 .96
ATP .98 1.09 1.00 .97 .96 1.12 1.01
KLA/ATP .94 1.04 1.05 1.00 .99 1.00 .98
Lama2
KLA  ATP  ATP+KLA
 NM_008481 laminin, alpha 2 (Lama2), mRNA [NM_008481] KLA .96 .99 .96 1.02 .95 1.00 .97
ATP 1.05 1.00 1.01 .94 1.01 1.04 .96
KLA/ATP .99 1.04 1.06 1.10 .98 .95 .97
Lama2
KLA  ATP  ATP+KLA
 U12147 laminin-2 alpha2 chain mRNA, complete cds. [U12147] KLA .96 1.00 .99 1.00 .98 1.02 1.03
ATP 1.01 .99 1.02 1.04 1.01 .99 1.02
KLA/ATP 1.00 1.01 1.00 1.01 .99 1.04 1.00
Lama3
KLA  ATP  ATP+KLA
 XM_140451 gb|PREDICTED: Mus musculus laminin, alpha 3, transcript variant 1 (Lama3), mRNA [XM_140451] KLA .76 .75 .73 .75 .71 .74 .67
ATP 1.04 1.12 1.05 1.20 .88 .73 .78
KLA/ATP .77 .81 .78 .82 .78 .71 .70
Lama4
KLA  ATP  ATP+KLA
 NM_010681 laminin, alpha 4 (Lama4), mRNA [NM_010681] KLA .99 .99 1.01 1.02 .98 .97 .96
ATP 1.00 1.08 1.05 1.05 1.03 1.04 .96
KLA/ATP 1.00 1.03 .93 1.00 .94 .90 .95
Lama5
KLA  ATP  ATP+KLA
 NM_001081171 laminin, alpha 5 (Lama5), mRNA [NM_001081171] KLA 1.11 1.07 1.09 1.00 .96 1.00 1.01
ATP 1.01 .99 1.03 1.01 1.00 .99 .99
KLA/ATP 1.12 1.08 1.05 1.04 .99 1.09 1.04
Lamb1-1
KLA  ATP  ATP+KLA
 NM_008482 laminin B1 subunit 1 (Lamb1-1), mRNA [NM_008482] KLA .93 .99 1.10 1.01 .95 1.00 .86
ATP .99 1.13 1.06 .99 1.07 .99 .97
KLA/ATP 1.00 1.06 .98 .95 .93 .89 1.04
Lamb2
KLA  ATP  ATP+KLA
 NM_008483 laminin, beta 2 (Lamb2), mRNA [NM_008483] KLA .93 .90 .95 .81 .79 .58 .37
ATP 1.01 1.09 .95 .99 .80 .81 .38
KLA/ATP .96 .87 1.00 .91 .72 .60 .38
Lamb3
KLA  ATP  ATP+KLA
 NM_008484 laminin, beta 3 (Lamb3), mRNA [NM_008484] KLA 1.00 .97 1.02 .98 1.00 1.04 .93
ATP 1.01 1.01 .91 .97 .89 1.04 1.03
KLA/ATP 1.00 .95 .97 1.00 .95 .87 1.02
Lamc1
KLA  ATP  ATP+KLA
 J03484 gb|Mouse laminin B2 chain mRNA, complete cds [J03484] KLA 1.14 1.01 1.04 .87 .82 .63 .75
ATP .99 1.09 1.07 1.14 1.36 2.38 .66
KLA/ATP 1.04 1.10 .95 1.12 1.30 1.70 .68
Lamc2
KLA  ATP  ATP+KLA
 AF106279 laminin gamma2 chain mRNA, partial cds. [AF106279] KLA 1.03 1.04 1.03 1.09 .97 .97 .98
ATP 1.04 1.04 1.16 1.48 1.46 1.29 1.26
KLA/ATP 1.04 1.00 1.03 1.06 .95 .99 1.08
Lamc2
KLA  ATP  ATP+KLA
 NM_008485 laminin, gamma 2 (Lamc2), mRNA [NM_008485] KLA 1.16 1.22 1.23 1.07 1.04 1.12 1.04
ATP 1.01 1.10 2.81 4.58 4.35 3.34 2.36
KLA/ATP 1.31 1.29 1.41 1.40 1.28 1.25 1.49
Lamc3
KLA  ATP  ATP+KLA
 AF083372 laminin 12 gamma 3 chain mRNA, complete cds. [AF083372] KLA .96 .94 .99 .96 .94 1.02 .88
ATP 1.06 1.00 .95 .98 .98 .99 1.02
KLA/ATP .90 .98 1.03 .95 .88 .97 .96
Lamc3
KLA  ATP  ATP+KLA
 NM_011836 laminin gamma 3 (Lamc3), mRNA [NM_011836] KLA 1.00 1.00 1.04 1.04 1.03 1.01 .97
ATP .99 1.06 1.00 .91 .98 .96 1.01
KLA/ATP .98 1.04 1.01 1.02 .96 .95 .98
Lef1
KLA  ATP  ATP+KLA
 NM_010703 lymphoid enhancer binding factor 1 (Lef1), mRNA [NM_010703] KLA 1.00 1.05 1.00 1.05 1.01 1.07 1.07
ATP .96 .98 1.03 1.09 .99 1.04 1.00
KLA/ATP 1.02 .98 .95 1.08 1.02 1.16 1.08
Map2k1
KLA  ATP  ATP+KLA
 NM_008927 mitogen-activated protein kinase kinase 1 (Map2k1), mRNA [NM_008927] KLA 1.82 2.00 2.31 2.03 2.51 2.20 1.51
ATP .99 1.14 .81 .87 .90 1.57 1.11
KLA/ATP 1.90 2.03 1.50 1.93 1.63 2.03 2.06
Map2k2
KLA  ATP  ATP+KLA
 NM_023138 mitogen-activated protein kinase kinase 2 (Map2k2), mRNA [NM_023138] KLA .96 1.01 1.09 .99 1.11 1.15 1.42
ATP 1.07 1.05 .74 .86 1.04 1.16 1.21
KLA/ATP 1.14 1.03 .68 .78 .85 1.01 1.20
Mapk1
KLA  ATP  ATP+KLA
 NM_001038663 mitogen-activated protein kinase 1 (Mapk1), transcript variant 2, mRNA [NM_001038663] KLA .97 1.03 .93 .86 .79 1.01 1.04
ATP .96 1.18 1.01 1.13 .84 1.04 1.16
KLA/ATP .99 .99 .84 .87 .63 .96 1.26
Mapk1
KLA  ATP  ATP+KLA
 NM_011949 mitogen-activated protein kinase 1 (Mapk1), transcript variant 1, mRNA [NM_011949] KLA .88 .80 .80 .73 .75 .76 .65
ATP .97 .96 1.06 .88 .90 .68 .48
KLA/ATP .82 .81 .78 .65 .64 .64 .45
Mapk10
KLA  ATP  ATP+KLA
 AK076990 adult male testis cDNA, RIKEN full-length enriched library, clone:4930597C01 product:mitogen activated protein kinase 10, full insert sequence. [AK076990] KLA 1.03 1.05 .98 1.04 .94 .95 1.02
ATP 1.00 .99 1.06 .97 1.01 .96 .99
KLA/ATP 1.07 1.01 .95 1.05 .82 .95 .87
Mapk10
KLA  ATP  ATP+KLA
 NM_009158 mitogen-activated protein kinase 10 (Mapk10), transcript variant 1, mRNA [NM_009158] KLA .95 1.00 .97 1.01 .99 1.01 .95
ATP 1.01 1.02 .98 1.01 1.04 1.01 .99
KLA/ATP 1.05 .99 1.01 .98 .92 .97 .98
Mapk3
KLA  ATP  ATP+KLA
 NM_011952 mitogen-activated protein kinase 3 (Mapk3), mRNA [NM_011952] KLA .81 .85 .88 .72 .79 .73 .90
ATP 1.13 1.30 .92 1.48 1.08 .68 1.03
KLA/ATP 1.01 1.01 .66 1.13 .77 .77 1.16
Mapk8
KLA  ATP  ATP+KLA
 AK162915 adult male spinal cord cDNA, RIKEN full-length enriched library, clone:A330031O19 product:mitogen activated protein kinase 8, full insert sequence [AK162915] KLA .94 .86 .80 .83 .77 .85 .83
ATP 1.08 1.12 .94 .80 .83 .71 .75
KLA/ATP .83 .81 .80 .74 .74 .75 .67
Mapk8
KLA  ATP  ATP+KLA
 AK163829 16 days embryo head cDNA, RIKEN full-length enriched library, clone:C130070A06 product:mitogen activated protein kinase 8, full insert sequence [AK163829] KLA .65 .61 .66 .70 .90 1.02 1.03
ATP .99 .94 1.68 1.44 1.75 1.84 1.10
KLA/ATP .63 .67 1.11 1.00 2.01 1.68 1.15
Mapk8
KLA  ATP  ATP+KLA
 NM_016700 mitogen-activated protein kinase 8 (Mapk8), mRNA [NM_016700] KLA .96 1.00 .94 .96 .94 .99 1.04
ATP 1.01 1.05 1.01 .99 1.03 .98 1.02
KLA/ATP .96 .97 .96 .97 .93 .94 .96
Mapk9
KLA  ATP  ATP+KLA
 NM_016961 mitogen-activated protein kinase 9 (Mapk9), transcript variant 2, mRNA [NM_016961] KLA 1.28 1.37 1.59 1.60 1.61 1.43 1.38
ATP 1.03 .99 .74 .71 .79 1.20 1.01
KLA/ATP 1.53 1.30 1.07 .99 .83 1.10 1.40
Mapk9
KLA  ATP  ATP+KLA
 NM_207692 mitogen-activated protein kinase 9 (Mapk9), transcript variant 1, mRNA [NM_207692] KLA 1.39 1.53 1.69 1.69 1.55 1.44 1.51
ATP .95 .92 .75 .85 .70 1.46 1.17
KLA/ATP 1.37 1.35 .99 1.18 .91 1.22 1.62
Max
KLA  ATP  ATP+KLA
 NM_008558 Max protein (Max), mRNA [NM_008558] KLA 3.40 3.25 4.09 4.53 3.19 2.71 1.19
ATP 1.17 1.09 1.13 .86 1.24 1.40 1.09
KLA/ATP 3.14 3.36 5.49 3.83 4.35 2.96 1.67
Mdm2
KLA  ATP  ATP+KLA
 NM_010786 transformed mouse 3T3 cell double minute 2 (Mdm2), mRNA [NM_010786] KLA 1.77 1.59 1.98 1.51 1.77 1.60 1.77
ATP 1.01 1.21 1.36 3.24 5.04 2.08 1.36
KLA/ATP 1.89 1.86 2.93 5.65 5.98 2.78 2.64
Met
KLA  ATP  ATP+KLA
 NM_008591 met proto-oncogene (Met), mRNA [NM_008591] KLA 3.56 3.71 3.68 3.79 4.24 5.89 6.95
ATP .98 .96 1.16 1.21 3.32 12.98 6.60
KLA/ATP 3.75 3.80 3.58 3.28 3.69 4.27 14.22
Mitf
KLA  ATP  ATP+KLA
 NM_008601 microphthalmia-associated transcription factor (Mitf), transcript variant 2, mRNA [NM_008601] KLA 2.09 2.20 1.58 2.38 2.33 2.27 1.52
ATP .93 .99 1.15 1.87 1.18 .89 1.16
KLA/ATP 1.83 2.28 2.35 2.87 1.26 .81 1.63
Mlh1
KLA  ATP  ATP+KLA
 NM_026810 mutL homolog 1 (E. coli) (Mlh1), mRNA [NM_026810] KLA .58 .55 .46 .47 .38 .49 .66
ATP .93 .95 1.06 1.02 .50 .80 .77
KLA/ATP .59 .56 .59 .55 .41 1.31 1.86
Mm.16788
2
KLA  ATP  ATP+KLA
 133778956 Unknown KLA 1.04 .90 .96 1.05 1.02 .98 1.00
ATP .97 1.04 .96 1.03 1.02 1.00 .95
KLA/ATP .95 1.05 1.08 1.00 .91 1.02 .93
Mm.18787
9
KLA  ATP  ATP+KLA
 149250519 Unknown KLA .98 .98 1.02 1.05 1.01 1.10 1.02
ATP 1.03 1.00 .98 1.02 1.02 1.04 .99
KLA/ATP .99 1.07 1.04 1.02 .94 .97 .93
Mm.19309
9
KLA  ATP  ATP+KLA
 46849811 Unknown KLA 1.32 1.36 1.42 1.17 1.06 .90 .58
ATP .98 1.12 1.41 1.81 1.44 1.14 .89
KLA/ATP 1.39 1.55 1.57 2.02 1.43 1.12 .74
Mm.21312
8
KLA  ATP  ATP+KLA
 141801344 Unknown KLA .96 .95 .83 .77 .52 .99 1.32
ATP .80 .82 1.09 .80 .83 1.19 1.46
KLA/ATP .78 .92 .98 .62 .71 .94 1.41
Mm.21516
1
KLA  ATP  ATP+KLA
 141801906 Unknown KLA 1.08 1.09 1.10 1.08 1.09 1.05 1.12
ATP .95 .94 1.05 1.16 1.05 1.08 1.14
KLA/ATP 1.07 1.15 1.16 1.16 1.10 1.14 1.14
Mm.22094
6
KLA  ATP  ATP+KLA
 27545180 Unknown KLA 1.00 .93 .97 1.05 1.06 1.29 1.13
ATP .90 .94 1.25 1.18 .85 .62 1.20
KLA/ATP .86 .99 1.14 .99 .83 .70 1.26
Mm.23625
6
KLA  ATP  ATP+KLA
 124487408 Unknown KLA .24 .22 .23 .24 .24 .30 .25
ATP .90 .95 1.24 .70 .34 .27 .28
KLA/ATP .21 .23 .31 .30 .30 .23 .18
Mm.24600
3
KLA  ATP  ATP+KLA
 161086914 Unknown KLA 10.04 10.23 11.14 8.37 5.02 2.48 2.15
ATP .96 1.08 1.11 1.79 4.88 8.01 1.29
KLA/ATP 9.96 11.13 9.87 10.92 7.51 7.35 6.26
Mm.25381
9
KLA  ATP  ATP+KLA
 118130676 Unknown KLA 1.81 1.88 1.96 1.62 1.89 2.44 1.56
ATP .92 .91 1.24 1.01 1.16 2.06 1.95
KLA/ATP 1.62 1.86 1.86 1.41 1.89 2.37 1.97
Mm.25806
5
KLA  ATP  ATP+KLA
 148747407 Unknown KLA 1.05 1.02 1.03 1.00 .99 1.05 .94
ATP .98 .98 1.03 1.02 .99 1.06 1.03
KLA/ATP 1.01 1.02 1.03 1.01 .96 .98 1.01
Mm.26687
1
KLA  ATP  ATP+KLA
 80978931 Unknown KLA .67 .63 .70 .83 1.66 1.43 1.54
ATP 1.20 1.24 1.22 1.26 1.80 .81 1.02
KLA/ATP .63 .56 .83 1.06 1.26 .70 1.34
Mm.27304
9
KLA  ATP  ATP+KLA
 119672895 Unknown KLA .23 .22 .22 .22 .30 .51 .16
ATP 1.08 1.05 .88 .78 .47 .09 .20
KLA/ATP .28 .22 .21 .24 .26 .22 .12
Mm.27574
2
KLA  ATP  ATP+KLA
 112983655 Unknown KLA 1.35 1.16 .94 .85 .45 .33 .31
ATP .90 .86 1.17 1.09 1.18 1.21 .38
KLA/ATP 1.12 1.22 1.19 .91 .90 .83 .33
Mm.28174
1
KLA  ATP  ATP+KLA
 94388259 Unknown KLA 1.68 1.72 2.01 1.72 1.18 1.02 .92
ATP .95 1.00 .84 .71 .53 .74 .81
KLA/ATP 1.79 1.76 1.40 1.17 .94 .74 .87
Mm.28722
8
KLA  ATP  ATP+KLA
 160707972 Unknown KLA 1.08 1.08 1.05 1.13 1.29 1.37 1.09
ATP 1.04 .96 1.15 .83 .88 1.18 1.09
KLA/ATP 1.06 .86 1.30 1.05 1.19 1.00 1.19
Mm.28924
8
KLA  ATP  ATP+KLA
 148747277 Unknown KLA 1.36 1.32 1.33 1.38 1.29 1.32 .98
ATP .86 .92 1.42 1.26 1.10 .95 .57
KLA/ATP 1.16 1.34 1.72 1.53 1.42 .87 .61
Mm.29279
KLA  ATP  ATP+KLA
 171543834 Unknown KLA .71 .71 .59 .63 .49 .40 .28
ATP .81 .73 .76 .63 .48 .39 .26
KLA/ATP .57 .64 .60 .55 .54 .37 .32
Mm.30793
2
KLA  ATP  ATP+KLA
 160333363 Unknown KLA .13 .12 .14 .16 .15 .18 .15
ATP .92 .94 1.12 .93 .58 .29 .31
KLA/ATP .11 .11 .18 .20 .28 .20 .19
Mm.33565
9
KLA  ATP  ATP+KLA
 160333365 Unknown KLA 5.54 4.69 3.93 3.03 2.00 1.91 1.69
ATP .98 .81 1.01 .78 .68 1.71 1.10
KLA/ATP 5.05 4.44 5.07 2.38 1.34 1.88 2.00
Mm.33981
2
KLA  ATP  ATP+KLA
 6679780 Unknown KLA 1.10 1.14 1.09 1.05 1.05 1.08 1.01
ATP .95 1.06 2.35 11.15 2.46 1.50 1.03
KLA/ATP 1.02 1.05 2.05 8.78 2.65 1.76 1.02
Mm.35584
KLA  ATP  ATP+KLA
 70909358 Unknown KLA .22 .25 .28 .33 .40 .77 .46
ATP 1.05 .96 1.08 .56 1.10 .79 .74
KLA/ATP .23 .25 .32 .25 .90 1.02 .60
Mm.39071
7
KLA  ATP  ATP+KLA
 77404401 Unknown KLA .86 .83 .88 1.03 1.07 1.12 .85
ATP .94 .88 1.33 1.11 1.09 1.69 1.47
KLA/ATP .78 .76 1.16 .94 1.13 1.52 1.17
Mm.4387
KLA  ATP  ATP+KLA
 133892666 Unknown KLA .85 .87 .85 .89 .77 .91 1.18
ATP 1.01 1.01 .87 1.07 .75 .86 .93
KLA/ATP .88 .86 .77 .81 .72 .91 .84
Mm.44463
KLA  ATP  ATP+KLA
 118129851 Unknown KLA 1.01 .98 .97 1.02 .93 1.06 1.05
ATP .97 1.01 1.04 1.06 1.02 1.08 .97
KLA/ATP 1.02 1.06 .95 1.04 1.09 1.14 1.03
Mm.45680
7
KLA  ATP  ATP+KLA
 157951728 Unknown KLA 1.00 1.02 1.05 .97 .99 .96 1.05
ATP 1.13 .98 1.00 1.06 1.02 .94 .98
KLA/ATP 1.11 .96 1.08 1.01 .99 1.01 .98
Mm.46002
4
KLA  ATP  ATP+KLA
 38348245 Unknown KLA 1.22 1.25 1.25 1.19 1.22 1.47 1.14
ATP 1.03 .94 1.01 1.01 2.67 2.31 1.37
KLA/ATP 1.35 1.19 1.27 1.22 1.99 1.83 1.45
Mm.46042
5
KLA  ATP  ATP+KLA
 145699103 Unknown KLA .97 1.06 1.00 1.00 1.04 1.00 1.06
ATP .98 1.03 .96 .96 1.00 1.05 .96
KLA/ATP .99 .95 1.04 .97 1.01 .98 .93
Mm.47351
0
KLA  ATP  ATP+KLA
 162287332 Unknown KLA 4.46 4.82 5.29 4.00 2.26 1.25 1.10
ATP 1.24 1.72 1.02 2.08 1.66 2.53 .55
KLA/ATP 6.11 7.67 4.29 6.99 3.11 2.86 2.30
Mm.4769
KLA  ATP  ATP+KLA
 31542830 Unknown KLA .93 .99 .86 .85 .75 .83 .80
ATP 1.01 1.00 .91 .83 .96 1.15 .84
KLA/ATP .95 .95 .92 .81 .85 1.12 .87
Mm.5055
KLA  ATP  ATP+KLA
 145966820 Unknown KLA 1.04 .96 1.04 .97 1.00 1.00 .97
ATP .95 .97 .96 .95 .97 .97 .98
KLA/ATP .88 1.04 1.07 1.02 .97 .98 .96
Mm.5126
KLA  ATP  ATP+KLA
 158508678 Unknown KLA .70 .71 .73 .79 .87 1.11 1.25
ATP 1.22 1.37 1.08 1.54 1.38 1.01 1.26
KLA/ATP .85 .83 .75 .90 1.12 .96 1.17
Mm.56964
KLA  ATP  ATP+KLA
 144227223 Unknown KLA .96 .99 1.00 .99 .97 1.01 1.05
ATP .99 .94 1.00 .94 .97 .99 .91
KLA/ATP 1.05 .97 1.02 .97 .91 1.00 1.02
Mm.56965
KLA  ATP  ATP+KLA
 6679704 Unknown KLA .96 1.05 1.06 1.01 1.05 .99 .98
ATP .95 .99 .93 1.05 .97 .96 1.02
KLA/ATP .95 1.01 1.03 1.02 .98 .98 .98
Mm.57199
KLA  ATP  ATP+KLA
 124256486 Unknown KLA .97 .97 .95 1.05 .96 .94 1.02
ATP .95 1.00 .96 .94 .97 1.05 .95
KLA/ATP .94 1.00 .86 1.02 .97 .96 .99
Mm.71710
KLA  ATP  ATP+KLA
 158966712 Unknown KLA 1.23 1.26 1.52 1.32 1.46 1.45 1.38
ATP .98 1.07 1.18 1.51 1.49 1.15 1.18
KLA/ATP 1.27 1.45 1.29 1.61 1.65 1.41 1.54
Mm.80682
KLA  ATP  ATP+KLA
 94369627 Unknown KLA .96 1.00 .97 .97 1.07 1.05 .99
ATP .97 1.02 .98 1.01 1.01 1.06 .96
KLA/ATP 1.00 .93 1.02 1.08 .98 .95 .97
Mm.81698
KLA  ATP  ATP+KLA
 158937287 Unknown KLA .95 1.02 1.04 .98 1.01 1.04 1.08
ATP 1.00 1.03 .97 1.00 1.03 .98 .96
KLA/ATP 1.07 1.00 .94 .98 1.03 1.05 .97
Mmp1a
KLA  ATP  ATP+KLA
 NM_032006 matrix metallopeptidase 1a (interstitial collagenase) (Mmp1a), mRNA [NM_032006] KLA 1.02 1.04 1.01 1.00 1.05 1.04 1.09
ATP .93 .99 1.07 1.13 1.04 1.05 1.05
KLA/ATP 1.01 1.02 .88 1.01 1.05 1.03 .98
Mmp2
KLA  ATP  ATP+KLA
 NM_008610 matrix metallopeptidase 2 (Mmp2), mRNA [NM_008610] KLA 1.12 1.24 1.48 1.26 1.44 1.19 1.09
ATP 1.05 1.01 1.07 1.08 .93 1.01 1.14
KLA/ATP 1.23 1.26 1.16 1.15 .95 1.11 1.04
Mmp9
KLA  ATP  ATP+KLA
 NM_013599 matrix metallopeptidase 9 (Mmp9), mRNA [NM_013599] KLA 1.49 1.65 1.43 1.32 1.46 1.33 2.10
ATP 1.03 1.05 1.12 1.36 1.17 2.27 5.92
KLA/ATP 1.51 1.64 1.35 1.78 1.34 1.20 2.96
Msh2
KLA  ATP  ATP+KLA
 AK051960 12 days embryo eyeball cDNA, RIKEN full-length enriched library, clone:D230024H20 product:mutS homolog 2 (E. coli), full insert sequence. [AK051960] KLA .94 .92 .89 1.00 .94 .98 .95
ATP .94 .81 1.04 .93 .99 .97 1.05
KLA/ATP .98 .92 .99 .95 .97 1.04 1.00
Msh2
KLA  ATP  ATP+KLA
 AK078775 15 days embryo male testis cDNA, RIKEN full-length enriched library, clone:8030473G08 product:mutS homolog 2 (E. coli), full insert sequence. [AK078775] KLA .71 .69 .72 .67 .69 .68 .66
ATP 1.05 .94 .66 .65 .70 .64 .74
KLA/ATP .70 .69 .67 .67 .67 .64 .60
Msh2
KLA  ATP  ATP+KLA
 NM_008628 mutS homolog 2 (E. coli) (Msh2), mRNA [NM_008628] KLA .33 .29 .22 .18 .14 .21 .28
ATP .91 .86 1.26 .84 .51 .19 .29
KLA/ATP .28 .28 .33 .21 .18 .15 .09
Msh3
KLA  ATP  ATP+KLA
 NM_010829 mutS homolog 3 (E. coli) (Msh3), mRNA [NM_010829] KLA .92 .89 .96 1.08 1.08 1.22 1.16
ATP 1.03 1.04 .96 .91 .65 .77 .95
KLA/ATP .88 .92 .92 .88 .86 1.31 2.25
Msh6
KLA  ATP  ATP+KLA
 NM_010830 mutS homolog 6 (E. coli) (Msh6), mRNA [NM_010830] KLA .12 .11 .11 .12 .14 .31 .35
ATP .89 .77 .98 .51 .38 .49 .35
KLA/ATP .11 .11 .15 .12 .22 .40 .40
Myc
KLA  ATP  ATP+KLA
 NM_010849 myelocytomatosis oncogene (Myc), mRNA [NM_010849] KLA .38 .31 .45 .45 .49 .35 .33
ATP 1.05 1.09 1.72 4.41 1.28 .45 .76
KLA/ATP .37 .30 .44 1.23 .34 .17 .19
Ncoa4
KLA  ATP  ATP+KLA
 NM_001033988 nuclear receptor coactivator 4 (Ncoa4), transcript variant 2, mRNA [NM_001033988] KLA .60 .64 .65 .63 .80 .99 .84
ATP 1.12 1.12 1.18 1.06 1.12 1.63 1.33
KLA/ATP .63 .63 .59 .58 .79 1.68 1.98
Nfkb1
KLA  ATP  ATP+KLA
 BC050841 nuclear factor of kappa light chain gene enhancer in B-cells 1, p105, mRNA (cDNA clone IMAGE:6392793), complete cds. [BC050841] KLA 5.81 4.96 4.77 3.21 3.37 2.00 1.71
ATP 1.39 1.52 3.25 12.63 13.64 4.80 1.08
KLA/ATP 7.21 8.69 19.53 23.93 11.70 2.85 2.01
Nfkb1
KLA  ATP  ATP+KLA
 M57999 gb|Mouse transcription factor NF-kappa-B DNA binding subunit mRNA, complete cds. [M57999] KLA 8.55 7.87 7.35 6.13 3.51 1.85 1.38
ATP .98 .96 1.21 3.06 5.29 4.67 .69
KLA/ATP 7.32 7.20 8.71 10.82 5.55 2.77 1.54
Nfkb2
KLA  ATP  ATP+KLA
 NM_019408 nuclear factor of kappa light polypeptide gene enhancer in B-cells 2, p49/p100 (Nfkb2), mRNA [NM_019408] KLA 7.31 7.92 7.95 6.42 6.41 4.42 2.81
ATP .99 .98 .72 1.48 2.80 5.31 1.44
KLA/ATP 8.25 7.93 6.51 7.68 5.08 4.38 4.86
Nfkbia
KLA  ATP  ATP+KLA
 NM_010907 nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha (Nfkbia), mRNA [NM_010907] KLA 18.65 18.46 13.63 17.88 14.25 9.17 7.92
ATP .91 1.09 7.11 32.39 17.44 10.49 1.72
KLA/ATP 15.57 17.66 15.73 23.91 13.83 10.73 9.48
Nkx3-1
KLA  ATP  ATP+KLA
 NM_010921 NK-3 transcription factor, locus 1 (Drosophila) (Nkx3-1), mRNA [NM_010921] KLA .91 .98 1.06 .98 1.01 1.02 1.08
ATP 1.03 .94 1.07 1.12 .97 1.03 1.04
KLA/ATP 1.04 1.01 1.01 1.05 1.04 1.12 .95
Nos2
KLA  ATP  ATP+KLA
 NM_010927 nitric oxide synthase 2, inducible, macrophage (Nos2), mRNA [NM_010927] KLA 13.50 16.36 25.65 23.25 24.78 15.99 6.48
ATP 1.03 1.03 1.48 1.66 1.65 5.55 1.70
KLA/ATP 16.01 17.41 19.06 25.50 20.84 29.92 29.80
Nras
KLA  ATP  ATP+KLA
 NM_010937 neuroblastoma ras oncogene (Nras), mRNA [NM_010937] KLA 1.20 1.22 1.27 1.20 1.09 .91 .84
ATP .98 .91 .69 .61 .59 .67 .78
KLA/ATP 1.22 1.14 .97 .79 .73 .61 .72
Ntrk1
KLA  ATP  ATP+KLA
 NM_001033124 neurotrophic tyrosine kinase, receptor, type 1 (Ntrk1), mRNA [NM_001033124] KLA .95 .96 1.03 1.03 .95 1.01 1.02
ATP 1.04 .98 .98 1.07 .99 1.01 1.02
KLA/ATP .97 1.03 1.10 1.02 1.05 1.00 .97
Pax8
KLA  ATP  ATP+KLA
 AK032920 12 days embryo male wolffian duct includes surrounding region cDNA, RIKEN full-length enriched library, clone:6720473A10 product:paired box gene 8, full insert sequence [AK032920] KLA .93 .91 .92 .91 1.02 1.07 1.04
ATP .98 1.06 .98 .99 1.00 1.02 .94
KLA/ATP .92 .95 .97 1.03 .98 .91 .89
Pax8
KLA  ATP  ATP+KLA
 NM_011040 paired box gene 8 (Pax8), mRNA [NM_011040] KLA 1.06 .96 1.07 1.01 1.03 .99 1.03
ATP 1.10 .97 1.01 1.04 .97 1.00 1.00
KLA/ATP 1.09 1.06 1.03 .94 .92 .92 .99
Pdgfa
KLA  ATP  ATP+KLA
 NM_008808 platelet derived growth factor, alpha (Pdgfa), mRNA [NM_008808] KLA .63 .56 .42 .34 .31 .33 .52
ATP .89 .80 .69 1.23 5.97 3.99 2.73
KLA/ATP .64 .53 .43 .77 3.48 3.78 2.37
Pdgfb
KLA  ATP  ATP+KLA
 NM_011057 platelet derived growth factor, B polypeptide (Pdgfb), mRNA [NM_011057] KLA .45 .43 .38 .46 .69 .48 .58
ATP .94 .95 .66 .74 .67 .77 1.06
KLA/ATP .43 .43 .37 .39 .52 .55 1.64
Pdgfra
KLA  ATP  ATP+KLA
 NM_011058 platelet derived growth factor receptor, alpha polypeptide (Pdgfra), transcript variant 1, mRNA [NM_011058] KLA 1.02 1.05 1.02 1.01 1.03 1.03 1.01
ATP 1.01 1.02 1.03 1.04 1.00 1.01 1.01
KLA/ATP 1.01 1.01 .99 1.03 1.02 1.03 1.01
Pdgfrb
KLA  ATP  ATP+KLA
 NM_008809 platelet derived growth factor receptor, beta polypeptide (Pdgfrb), mRNA [NM_008809] KLA 4.85 5.49 4.56 3.94 3.71 2.05 1.51
ATP .99 1.00 1.11 1.27 1.02 1.83 1.23
KLA/ATP 5.09 5.86 4.30 2.51 1.74 1.84 3.23
Pgf
KLA  ATP  ATP+KLA
 NM_008827 placental growth factor (Pgf), mRNA [NM_008827] KLA 1.59 1.43 1.58 1.66 1.51 1.67 1.19
ATP .94 1.05 1.49 3.36 5.65 4.56 3.89
KLA/ATP 1.64 1.61 1.95 2.17 3.19 4.33 4.95
Pias2
KLA  ATP  ATP+KLA
 NM_008602 protein inhibitor of activated STAT 2 (Pias2), mRNA [NM_008602] KLA .85 .84 .82 .87 .80 1.05 1.03
ATP .88 .95 1.02 .86 .93 1.17 1.16
KLA/ATP .76 .83 .91 .77 .93 1.15 1.16
Pik3ca
KLA  ATP  ATP+KLA
 ENSMUST00000108243 ens|Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha isoform (EC 2.7.1.153) (PI3-kinase p110 subunit alpha) (PtdIns-3- kinase p110) (PI3K). [Source:Uniprot/SWISSPROT;Acc:P42337] [ENSMUST00000108243] KLA 1.07 1.01 .91 .90 .98 .96 .86
ATP 1.03 .87 1.12 .63 1.22 1.86 .60
KLA/ATP 1.05 .82 .91 .61 1.17 1.26 .63
Pik3ca
KLA  ATP  ATP+KLA
 NM_008839 phosphatidylinositol 3-kinase, catalytic, alpha polypeptide (Pik3ca), mRNA [NM_008839] KLA 1.15 1.11 1.05 .82 .99 1.03 1.27
ATP .98 1.00 .79 .75 .96 1.32 1.10
KLA/ATP 1.10 .98 .64 .72 .80 1.20 1.41
Pik3cb
KLA  ATP  ATP+KLA
 NM_029094 phosphatidylinositol 3-kinase, catalytic, beta polypeptide (Pik3cb), mRNA [NM_029094] KLA 1.06 1.06 1.03 .73 .68 .98 1.69
ATP 1.04 1.21 .95 1.02 .85 .93 1.73
KLA/ATP 1.15 1.27 .73 .83 .58 .81 1.81
Pik3cd
KLA  ATP  ATP+KLA
 NM_008840 phosphatidylinositol 3-kinase catalytic delta polypeptide (Pik3cd), transcript variant 1, mRNA [NM_008840] KLA 2.28 2.42 3.10 4.17 3.35 2.31 1.34
ATP 1.02 .91 .99 .63 .30 .67 .80
KLA/ATP 2.14 2.23 2.70 1.51 1.17 .85 .72
Pik3cd
KLA  ATP  ATP+KLA
 U86587 phosphatidylinositol 3-kinase catalytic subunit p110 delta mRNA, complete cds. [U86587] KLA 2.21 2.24 3.71 3.17 3.67 2.66 1.48
ATP 1.00 1.03 .93 .96 .46 .75 .97
KLA/ATP 2.27 2.32 1.97 2.02 1.01 .99 .98
Pik3cg
KLA  ATP  ATP+KLA
 NM_020272 phosphoinositide-3-kinase, catalytic, gamma polypeptide (Pik3cg), mRNA [NM_020272] KLA .53 .53 .61 .64 .97 .86 .79
ATP 1.01 1.13 .88 .89 .52 .53 .53
KLA/ATP .58 .53 .43 .60 .40 .43 .62
Pik3r1
KLA  ATP  ATP+KLA
 NM_001077495 phosphatidylinositol 3-kinase, regulatory subunit, polypeptide 1 (p85 alpha) (Pik3r1), transcript variant 2, mRNA [NM_001077495] KLA 1.05 1.07 1.03 1.00 1.01 1.20 .85
ATP .97 1.02 1.48 1.42 1.76 1.33 1.23
KLA/ATP 1.11 1.12 1.06 1.17 1.24 .99 1.12
Pik3r2
KLA  ATP  ATP+KLA
 NM_008841 phosphatidylinositol 3-kinase, regulatory subunit, polypeptide 2 (p85 beta) (Pik3r2), mRNA [NM_008841] KLA .50 .50 .48 .43 .46 .66 .75
ATP .78 .68 .45 .43 .28 .57 1.37
KLA/ATP .49 .38 .32 .33 .38 .67 1.10
Pik3r3
KLA  ATP  ATP+KLA
 NM_181585 phosphatidylinositol 3 kinase, regulatory subunit, polypeptide 3 (p55) (Pik3r3), mRNA [NM_181585] KLA 1.59 1.49 1.37 1.17 1.05 1.55 1.41
ATP 1.12 1.00 1.33 1.70 2.01 2.37 2.02
KLA/ATP 1.63 1.54 1.58 1.70 2.43 2.68 1.92
Pik3r5
KLA  ATP  ATP+KLA
 NM_177320 phosphoinositide-3-kinase, regulatory subunit 5, p101 (Pik3r5), mRNA [NM_177320] KLA 3.57 3.58 4.16 3.54 4.11 2.59 2.39
ATP 1.08 1.08 .93 1.67 3.11 1.88 1.34
KLA/ATP 3.91 3.70 3.30 3.80 2.70 2.04 3.00
Plcg2
KLA  ATP  ATP+KLA
 NM_172285 phospholipase C, gamma 2 (Plcg2), mRNA [NM_172285] KLA .76 .74 .68 .66 .71 .92 .95
ATP .96 .90 .95 .87 .81 .79 .91
KLA/ATP .76 .71 .69 .62 .72 .78 .68
Pml
KLA  ATP  ATP+KLA
 NM_008884 promyelocytic leukemia (Pml), transcript variant 1, mRNA [NM_008884] KLA 5.73 6.01 7.28 6.76 5.85 5.36 2.28
ATP 1.07 1.10 .92 .89 .97 3.78 2.67
KLA/ATP 6.48 6.51 6.81 8.78 6.61 7.57 6.55
Ppard
KLA  ATP  ATP+KLA
 NM_011145 peroxisome proliferator activator receptor delta (Ppard), mRNA [NM_011145] KLA 1.04 .97 1.09 1.04 1.14 .99 1.11
ATP 1.03 .97 .94 1.01 1.36 1.49 1.11
KLA/ATP 1.00 1.00 .94 1.07 1.20 1.29 1.17
Pparg
KLA  ATP  ATP+KLA
 NM_011146 peroxisome proliferator activated receptor gamma (Pparg), mRNA [NM_011146] KLA .32 .28 .31 .45 .38 .35 .49
ATP .96 1.01 1.28 1.65 1.83 .57 .77
KLA/ATP .30 .29 .36 .53 1.23 .72 .55
Prkca
KLA  ATP  ATP+KLA
 NM_011101 protein kinase C, alpha (Prkca), mRNA [NM_011101] KLA 1.00 .96 .94 .95 .95 .89 .96
ATP 1.00 1.03 .91 .94 .82 .87 1.13
KLA/ATP 1.02 .95 .91 .86 .78 .84 .94
Prkcb1
KLA  ATP  ATP+KLA
 NM_008855 protein kinase C, beta 1 (Prkcb1), mRNA [NM_008855] KLA .92 .95 .93 .78 .77 1.08 1.83
ATP 1.03 1.12 1.09 1.23 .90 2.08 .96
KLA/ATP .98 .99 .82 .89 .62 1.01 1.08
Prkcc
KLA  ATP  ATP+KLA
 NM_011102 protein kinase C, gamma (Prkcc), mRNA [NM_011102] KLA 1.02 1.04 1.11 1.04 .96 1.02 1.05
ATP .98 .98 1.05 1.03 1.08 .96 .95
KLA/ATP 1.21 1.16 1.09 1.07 1.04 .98 .93
Ptch1
KLA  ATP  ATP+KLA
 AK147626 cDNA, RIKEN full-length enriched library, clone:M5C1096C04 product:patched homolog 1, full insert sequence [AK147626] KLA 1.35 1.31 1.25 1.03 1.06 .89 .89
ATP 1.00 1.08 1.01 .90 1.09 1.20 1.03
KLA/ATP 1.27 1.29 1.34 1.24 1.22 1.21 1.01
Ptch1
KLA  ATP  ATP+KLA
 NM_008957 patched homolog 1 (Ptch1), mRNA [NM_008957] KLA 1.10 1.05 1.10 1.03 .99 .99 1.01
ATP 1.02 1.01 1.04 1.01 1.07 1.14 1.05
KLA/ATP 1.12 1.10 1.05 1.08 1.06 1.11 .98
Ptch2
KLA  ATP  ATP+KLA
 BC058397 patched homolog 2, mRNA (cDNA clone IMAGE:6832070), partial cds [BC058397] KLA 1.10 1.01 1.01 .94 .99 1.07 .96
ATP .92 .99 1.07 1.03 .98 .99 1.01
KLA/ATP 1.01 .98 .98 1.03 1.03 .98 .98
Ptch2
KLA  ATP  ATP+KLA
 NM_008958 patched homolog 2 (Ptch2), mRNA [NM_008958] KLA 1.03 1.13 1.11 1.13 1.14 1.19 1.15
ATP 1.01 .97 1.08 1.10 1.03 1.15 1.07
KLA/ATP 1.05 1.05 .98 1.16 1.25 1.27 1.22
Pten
KLA  ATP  ATP+KLA
 NM_008960 phosphatase and tensin homolog (Pten), mRNA [NM_008960] KLA .79 .73 .61 .59 .56 .70 1.00
ATP 1.04 1.11 1.07 1.12 1.03 1.38 .83
KLA/ATP .75 .69 .60 .74 .93 1.09 1.24
Ptgs2
KLA  ATP  ATP+KLA
 NM_011198 prostaglandin-endoperoxide synthase 2 (Ptgs2), mRNA [NM_011198] KLA 181.04 220.88 218.58 132.79 103.05 22.69 18.02
ATP 2.47 9.45 52.13 208.62 271.22 306.11 6.86
KLA/ATP 233.39 387.29 617.86 ###.## 608.44 290.80 112.22
Ptk2
KLA  ATP  ATP+KLA
 NM_007982 PTK2 protein tyrosine kinase 2 (Ptk2), mRNA [NM_007982] KLA .99 .99 1.02 1.04 1.09 1.22 1.57
ATP 1.04 1.09 .95 .98 .67 .96 .87
KLA/ATP .99 1.03 .87 .93 .81 1.16 1.04
Rac1
KLA  ATP  ATP+KLA
 NM_009007 RAS-related C3 botulinum substrate 1 (Rac1), mRNA [NM_009007] KLA 1.02 1.01 1.02 .99 1.03 1.15 1.08
ATP .99 1.15 1.01 1.27 1.06 1.20 1.06
KLA/ATP 1.00 1.04 .88 1.16 .91 1.21 1.38
Rac2
KLA  ATP  ATP+KLA
 NM_009008 RAS-related C3 botulinum substrate 2 (Rac2), mRNA [NM_009008] KLA 1.55 1.68 1.86 2.15 3.36 3.59 3.74
ATP 1.13 1.16 .74 .99 .84 .91 1.66
KLA/ATP 1.59 1.71 1.19 1.56 1.21 1.60 3.48
Rac3
KLA  ATP  ATP+KLA
 NM_133223 RAS-related C3 botulinum substrate 3 (Rac3), mRNA [NM_133223] KLA 2.03 2.20 2.64 2.18 2.95 2.29 1.41
ATP 1.02 1.12 .94 1.42 1.16 .84 .87
KLA/ATP 2.30 2.32 1.57 2.55 1.75 1.47 1.61
Rad51
KLA  ATP  ATP+KLA
 NM_011234 RAD51 homolog (S. cerevisiae) (Rad51), mRNA [NM_011234] KLA .44 .39 .39 .29 .16 .14 .12
ATP 1.13 .90 .69 .63 .38 .25 .09
KLA/ATP .47 .38 .35 .23 .18 .10 .06
Raf1
KLA  ATP  ATP+KLA
 AK036317 16 days neonate cerebellum cDNA, RIKEN full-length enriched library, clone:9630056E02 product:v-raf-1 leukemia viral oncogene 1, full insert sequence. [AK036317] KLA 1.47 1.34 1.55 1.29 1.59 1.32 1.46
ATP 1.05 .98 .54 .63 3.32 2.07 1.01
KLA/ATP 1.57 1.33 .79 .96 2.26 1.38 1.35
Raf1
KLA  ATP  ATP+KLA
 NM_029780 v-raf-leukemia viral oncogene 1 (Raf1), mRNA [NM_029780] KLA 1.65 1.64 1.93 1.77 1.77 1.72 1.81
ATP .95 .96 .83 .80 2.22 2.92 1.19
KLA/ATP 1.68 1.64 1.39 1.32 1.85 2.50 2.06
Rala
KLA  ATP  ATP+KLA
 NM_019491 v-ral simian leukemia viral oncogene homolog A (ras related) (Rala), mRNA [NM_019491] KLA 1.02 1.05 1.01 1.18 1.31 1.22 2.24
ATP 1.06 1.07 1.08 1.30 1.44 1.43 1.34
KLA/ATP 1.04 1.08 .98 1.07 1.28 1.34 2.01
Ralb
KLA  ATP  ATP+KLA
 NM_022327 v-ral simian leukemia viral oncogene homolog B (ras related) (Ralb), mRNA [NM_022327] KLA 1.10 .98 .89 1.12 1.14 1.47 1.04
ATP .89 .82 .88 .72 .81 1.28 .97
KLA/ATP .84 .85 .85 .73 1.00 1.36 1.20
Ralbp1
KLA  ATP  ATP+KLA
 NM_009067 ralA binding protein 1 (Ralbp1), mRNA [NM_009067] KLA .71 .64 .67 .63 .67 .63 .77
ATP 1.09 1.05 .78 .73 .68 .72 .78
KLA/ATP .79 .73 .55 .50 .54 .52 .61
Ralgds
KLA  ATP  ATP+KLA
 NM_009058 ral guanine nucleotide dissociation stimulator (Ralgds), mRNA [NM_009058] KLA 4.29 4.39 3.93 3.90 3.91 3.29 3.29
ATP .91 .92 1.56 3.84 7.41 6.08 2.29
KLA/ATP 3.37 4.34 5.23 7.26 10.22 6.72 6.05
Rara
KLA  ATP  ATP+KLA
 NM_009024 retinoic acid receptor, alpha (Rara), mRNA [NM_009024] KLA .83 .88 .84 .91 .94 .95 .88
ATP 1.00 1.12 1.01 .97 1.19 .93 1.20
KLA/ATP .93 .90 .88 .91 .95 .95 .91
Rarb
KLA  ATP  ATP+KLA
 NM_011243 retinoic acid receptor, beta (Rarb), mRNA [NM_011243] KLA 1.03 1.01 1.01 1.02 1.02 .98 1.00
ATP .99 1.00 1.02 1.01 .98 .98 .99
KLA/ATP 1.02 1.02 1.00 .99 .98 .98 .99
Rarb
KLA  ATP  ATP+KLA
 S92180 gb|Mus sp. retinoic acid receptor isoform RAR-beta 4 mRNA, partial cds. [S92180] KLA 1.04 .97 .96 1.04 1.01 1.05 1.00
ATP 1.03 .95 1.10 .96 1.03 1.05 .98
KLA/ATP 1.01 .97 1.06 .97 .98 .93 1.05
Rassf1
KLA  ATP  ATP+KLA
 NM_019713 Ras association (RalGDS/AF-6) domain family member 1 (Rassf1), mRNA [NM_019713] KLA .96 1.07 .99 1.34 1.55 2.00 1.74
ATP .94 .98 .99 1.14 1.94 2.54 2.03
KLA/ATP .99 1.16 1.01 1.28 2.98 2.91 4.25
Rassf5
KLA  ATP  ATP+KLA
 NM_018750 Ras association (RalGDS/AF-6) domain family member 5 (Rassf5), mRNA [NM_018750] KLA .44 .45 .57 .64 1.03 .77 .64
ATP 1.06 1.34 1.12 2.16 1.77 .35 .64
KLA/ATP .55 .48 .39 .79 .78 .39 .43
Rb1
KLA  ATP  ATP+KLA
 NM_009029 retinoblastoma 1 (Rb1), mRNA [NM_009029] KLA .67 .60 .55 .51 .46 .75 .79
ATP 1.04 1.01 1.12 .86 .59 .43 .76
KLA/ATP .64 .59 .58 .46 .36 .30 .65
Rbx1
KLA  ATP  ATP+KLA
 NM_019712 ring-box 1 (Rbx1), mRNA [NM_019712] KLA 1.04 1.01 .98 1.09 1.06 1.14 1.09
ATP .92 .89 1.13 1.16 1.68 1.07 .83
KLA/ATP .99 .99 1.25 1.31 2.63 2.06 .67
Rela
KLA  ATP  ATP+KLA
 NM_009045 v-rel reticuloendotheliosis viral oncogene homolog A (avian) (Rela), mRNA [NM_009045] KLA 2.05 2.05 2.07 1.75 1.83 1.58 1.33
ATP 1.03 1.08 1.10 1.44 1.61 2.48 1.05
KLA/ATP 2.17 2.27 2.05 2.47 1.93 2.35 2.02
Ret
KLA  ATP  ATP+KLA
 NM_009050 ret proto-oncogene (Ret), transcript variant 2, mRNA [NM_009050] KLA 1.00 1.00 1.04 1.02 1.03 1.01 1.02
ATP 1.02 .98 1.01 1.00 .99 1.01 1.01
KLA/ATP 1.01 .97 1.02 1.01 1.00 1.00 .98
Rhoa
KLA  ATP  ATP+KLA
 NM_016802 ras homolog gene family, member A (Rhoa), mRNA [NM_016802] KLA .93 1.00 1.07 .97 1.08 1.06 1.02
ATP .93 .88 .49 .61 .63 .78 1.05
KLA/ATP .94 .92 .59 .63 .61 .78 1.12
Runx1
KLA  ATP  ATP+KLA
 NM_001111023 runt related transcription factor 1 (Runx1), transcript variant 3, mRNA [NM_001111023] KLA 1.14 1.21 1.40 1.59 1.67 1.51 1.33
ATP 1.02 1.33 1.55 2.35 2.05 1.69 1.70
KLA/ATP 1.18 1.43 1.51 2.75 2.38 1.88 2.62
Runx1
KLA  ATP  ATP+KLA
 NM_009821 runt related transcription factor 1 (Runx1), transcript variant 4, mRNA [NM_009821] KLA .74 .75 .93 1.11 1.15 .87 .89
ATP 1.23 1.19 1.06 1.78 1.35 .47 .76
KLA/ATP .77 .76 .74 1.41 1.55 .48 .61
Runx1t1
KLA  ATP  ATP+KLA
 NM_009822 runt-related transcription factor 1; translocated to, 1 (cyclin D-related) (Runx1t1), transcript variant 3, mRNA [NM_009822] KLA .99 .95 .96 1.01 1.05 1.01 .97
ATP 1.05 1.05 1.02 1.02 1.02 1.05 1.06
KLA/ATP 1.01 1.00 .97 1.01 .99 1.01 1.10
Rxra
KLA  ATP  ATP+KLA
 NM_011305 retinoid X receptor alpha (Rxra), mRNA [NM_011305] KLA .53 .55 .50 .52 .54 .85 1.09
ATP .95 1.00 1.18 1.00 .82 1.20 1.65
KLA/ATP .57 .55 .58 .55 .67 1.07 1.57
Rxrb
KLA  ATP  ATP+KLA
 NM_011306 retinoid X receptor beta (Rxrb), mRNA [NM_011306] KLA .71 .75 .75 .76 .83 .81 .89
ATP 1.04 1.13 .94 1.20 1.13 .81 .75
KLA/ATP .80 .86 .72 .85 .83 .93 .92
Rxrg
KLA  ATP  ATP+KLA
 NM_009107 retinoid X receptor gamma (Rxrg), mRNA [NM_009107] KLA .98 1.07 1.07 1.00 1.00 1.00 1.07
ATP 1.02 1.03 1.06 1.06 1.11 1.01 .99
KLA/ATP .95 .97 1.05 1.05 1.09 .98 1.06
Sfpi1
KLA  ATP  ATP+KLA
 NM_011355 SFFV proviral integration 1 (Sfpi1), mRNA [NM_011355] KLA 2.54 2.77 2.96 2.31 3.22 2.44 2.29
ATP 1.17 1.55 .79 1.96 1.49 1.23 1.66
KLA/ATP 3.35 3.40 1.30 3.78 1.70 1.80 3.18
Shh
KLA  ATP  ATP+KLA
 NM_009170 sonic hedgehog (Shh), mRNA [NM_009170] KLA .99 1.01 1.02 .99 1.00 1.02 1.02
ATP 1.00 .99 1.00 .98 1.01 1.00 1.01
KLA/ATP 1.00 1.01 1.03 1.02 1.02 1.03 1.00
Skp2
KLA  ATP  ATP+KLA
 AF083215 SCF complex protein Skp2 mRNA, complete cds. [AF083215] KLA .36 .37 .34 .37 .44 .78 .60
ATP 1.05 1.35 .85 .66 .83 .54 .76
KLA/ATP .33 .39 .37 .37 .65 .73 .62
Slc2a1
KLA  ATP  ATP+KLA
 NM_011400 solute carrier family 2 (facilitated glucose transporter), member 1 (Slc2a1), mRNA [NM_011400] KLA 1.31 1.46 1.10 1.68 1.75 1.95 2.34
ATP .88 .90 1.32 1.99 3.40 10.49 1.93
KLA/ATP 1.13 1.25 1.71 2.14 3.71 6.31 4.63
Smad2
KLA  ATP  ATP+KLA
 NM_010754 MAD homolog 2 (Drosophila) (Smad2), mRNA [NM_010754] KLA 1.05 1.08 1.04 1.17 1.40 1.43 1.59
ATP 1.01 1.02 1.16 1.14 1.15 1.32 1.34
KLA/ATP 1.00 .99 .97 1.09 1.40 1.14 1.40
Smad3
KLA  ATP  ATP+KLA
 NM_016769 MAD homolog 3 (Drosophila) (Smad3), mRNA [NM_016769] KLA .64 .60 .57 .64 .70 1.25 1.52
ATP 1.02 1.02 .84 1.21 2.42 .90 1.19
KLA/ATP .64 .60 .65 .66 1.29 1.26 2.26
Smad4
KLA  ATP  ATP+KLA
 NM_008540 MAD homolog 4 (Drosophila) (Smad4), mRNA [NM_008540] KLA 1.11 1.11 1.13 1.09 1.02 .98 1.08
ATP 1.00 1.04 .92 .76 1.67 1.44 .92
KLA/ATP 1.09 1.01 .87 .89 1.64 1.43 .99
Smo
KLA  ATP  ATP+KLA
 NM_176996 smoothened homolog (Drosophila) (Smo), mRNA [NM_176996] KLA .67 .64 .53 .53 .39 .30 .20
ATP .78 .69 .74 .61 .43 .30 .21
KLA/ATP .56 .53 .57 .51 .42 .29 .24
Sos1
KLA  ATP  ATP+KLA
 NM_009231 Son of sevenless homolog 1 (Drosophila) (Sos1), mRNA [NM_009231] KLA 2.36 2.40 3.42 3.15 2.78 1.81 1.71
ATP .99 1.00 .99 1.15 1.14 1.25 1.24
KLA/ATP 2.41 2.26 1.95 2.44 1.47 1.66 1.37
Sos2
KLA  ATP  ATP+KLA
 XM_127051 gb|PREDICTED: Mus musculus Son of sevenless homolog 2 (Drosophila) (Sos2), mRNA [XM_127051] KLA .81 .77 .79 .92 1.04 1.06 1.20
ATP 1.00 1.00 1.09 .79 .68 .81 .94
KLA/ATP .77 .69 .71 .60 .64 .77 1.07
Stat1
KLA  ATP  ATP+KLA
 NM_009283 signal transducer and activator of transcription 1 (Stat1), mRNA [NM_009283] KLA 2.90 2.72 3.00 3.64 4.58 6.51 5.58
ATP 1.01 .92 .89 .72 .51 2.22 3.07
KLA/ATP 2.73 2.65 2.34 1.95 1.99 4.70 8.66
Stat3
KLA  ATP  ATP+KLA
 NM_213659 signal transducer and activator of transcription 3 (Stat3), transcript variant 1, mRNA [NM_213659] KLA 4.36 4.42 4.67 6.02 4.95 3.45 1.46
ATP 1.01 .97 1.07 1.17 2.47 4.04 1.47
KLA/ATP 4.02 4.57 6.65 6.51 7.06 7.39 3.61
Stat5a
KLA  ATP  ATP+KLA
 NM_011488 signal transducer and activator of transcription 5A (Stat5a), mRNA [NM_011488] KLA 8.23 8.24 6.89 4.88 4.35 1.98 1.01
ATP 1.07 1.14 1.07 1.26 3.23 3.14 1.52
KLA/ATP 8.70 9.53 7.33 6.68 4.32 2.73 1.72
Stat5b
KLA  ATP  ATP+KLA
 AK137889 16 days neonate thymus cDNA, RIKEN full-length enriched library, clone:A130035C01 product:unclassifiable, full insert sequence. [AK137889] KLA 1.10 1.01 .98 .90 1.03 .93 .88
ATP .90 .87 .61 .69 1.01 .97 .89
KLA/ATP 1.12 1.00 .87 .85 .95 1.07 .83
Stat5b
KLA  ATP  ATP+KLA
 NM_011489 signal transducer and activator of transcription 5B (Stat5b), transcript variant 1, mRNA [NM_011489] KLA 2.91 2.81 3.42 2.69 2.23 1.95 1.32
ATP .99 1.04 1.16 .97 1.00 1.84 2.09
KLA/ATP 2.96 3.05 3.17 2.99 1.86 1.87 3.40
Stk36
KLA  ATP  ATP+KLA
 NM_175031 serine/threonine kinase 36 (fused homolog, Drosophila) (Stk36), mRNA [NM_175031] KLA .94 .91 .93 1.02 1.06 1.16 1.13
ATP 1.03 1.01 .99 .96 .85 .96 1.25
KLA/ATP .94 .91 1.00 .93 .88 1.06 1.37
Stk4
KLA  ATP  ATP+KLA
 NM_021420 serine/threonine kinase 4 (Stk4), mRNA [NM_021420] KLA 2.16 2.04 1.77 1.64 1.71 1.70 1.37
ATP 1.04 1.05 .96 .91 .93 1.17 1.53
KLA/ATP 2.08 2.13 1.73 1.59 1.25 1.35 1.88
Sufu
KLA  ATP  ATP+KLA
 BC048168 suppressor of fused homolog (Drosophila), mRNA (cDNA clone MGC:61295 IMAGE:6821477), complete cds [BC048168] KLA .88 .82 .87 .84 .93 .84 .93
ATP 1.17 1.08 .86 .71 .73 .95 .83
KLA/ATP .99 .92 .69 .66 .71 .87 .92
Sufu
KLA  ATP  ATP+KLA
 NM_015752 suppressor of fused homolog (Drosophila) (Sufu), transcript variant 1, mRNA [NM_015752] KLA 1.24 1.24 1.28 1.22 1.27 1.21 1.15
ATP 1.00 1.10 1.01 .99 .90 1.72 1.98
KLA/ATP 1.19 1.24 1.19 1.10 .93 1.54 2.62
Tceb1
KLA  ATP  ATP+KLA
 NM_026456 transcription elongation factor B (SIII), polypeptide 1 (Tceb1), mRNA [NM_026456] KLA 1.27 1.21 1.25 1.65 1.46 1.21 1.26
ATP 1.11 1.01 1.44 1.34 1.46 1.17 .74
KLA/ATP 1.20 1.48 2.16 1.77 1.56 1.13 .89
Tceb2
KLA  ATP  ATP+KLA
 NM_026305 transcription elongation factor B (SIII), polypeptide 2 (Tceb2), mRNA [NM_026305] KLA .99 1.00 .96 1.01 1.04 .96 1.24
ATP 1.15 1.17 1.03 1.36 1.25 1.05 1.27
KLA/ATP 1.07 1.13 1.08 1.30 1.21 1.23 1.56
Tcf3
KLA  ATP  ATP+KLA
 NM_001079822 transcription factor 3 (Tcf3), transcript variant 1, mRNA [NM_001079822] KLA 1.03 .98 1.01 .98 .98 1.03 1.01
ATP 1.00 1.02 1.00 1.06 1.10 1.07 .99
KLA/ATP 1.07 .99 .97 1.05 1.05 1.11 .96
Tcf7
KLA  ATP  ATP+KLA
 NM_009331 transcription factor 7, T-cell specific (Tcf7), mRNA [NM_009331] KLA 1.00 1.01 1.03 1.00 .98 1.01 1.07
ATP .99 .98 1.02 1.03 1.03 1.00 1.01
KLA/ATP 1.00 1.03 1.04 1.02 1.04 1.02 1.00
Tcf7l2
KLA  ATP  ATP+KLA
 NM_009333 transcription factor 7-like 2, T-cell specific, HMG-box (Tcf7l2), mRNA [NM_009333] KLA 1.01 1.12 1.11 1.31 1.06 1.34 1.29
ATP 1.04 1.05 .94 1.06 .90 .81 .96
KLA/ATP 1.08 1.11 1.05 1.18 1.04 1.02 1.42
Tfg
KLA  ATP  ATP+KLA
 AK039139 adult male hypothalamus cDNA, RIKEN full-length enriched library, clone:A230101M06 product:unclassifiable, full insert sequence [AK039139] KLA 1.12 1.11 1.12 1.05 1.12 1.04 1.02
ATP .93 .85 .91 .95 .96 1.00 .90
KLA/ATP 1.11 1.01 .92 .89 .97 1.03 .90
Tfg
KLA  ATP  ATP+KLA
 NM_019678 Trk-fused gene (Tfg), mRNA [NM_019678] KLA 1.81 1.71 2.04 2.24 1.93 1.42 1.01
ATP .94 .96 1.09 .95 .76 1.04 .84
KLA/ATP 1.56 1.62 1.71 1.63 1.45 1.49 .85
Tgfa
KLA  ATP  ATP+KLA
 NM_031199 transforming growth factor alpha (Tgfa), mRNA [NM_031199] KLA 1.01 .99 1.00 1.03 1.01 1.04 1.04
ATP 1.01 1.04 1.02 1.02 1.02 1.01 1.05
KLA/ATP 1.01 1.02 1.02 1.02 1.02 1.06 1.02
Tgfb1
KLA  ATP  ATP+KLA
 NM_011577 transforming growth factor, beta 1 (Tgfb1), mRNA [NM_011577] KLA .87 .89 .90 .70 .83 .77 1.12
ATP 1.20 1.41 .80 1.49 1.11 .93 .99
KLA/ATP 1.10 1.20 .53 1.05 .66 .85 .90
Tgfb2
KLA  ATP  ATP+KLA
 NM_009367 transforming growth factor, beta 2 (Tgfb2), mRNA [NM_009367] KLA 1.01 .91 .98 .98 .92 1.19 .96
ATP .99 1.03 1.00 1.02 .99 1.07 .93
KLA/ATP 1.02 .99 1.03 .98 1.04 1.06 .96
Tgfb3
KLA  ATP  ATP+KLA
 NM_009368 transforming growth factor, beta 3 (Tgfb3), mRNA [NM_009368] KLA .67 .64 .58 .56 .49 .52 .61
ATP .90 .92 1.33 1.08 .78 .65 .74
KLA/ATP .58 .60 .74 .61 .76 1.36 1.51
Tgfbr1
KLA  ATP  ATP+KLA
 NM_009370 transforming growth factor, beta receptor I (Tgfbr1), mRNA [NM_009370] KLA .73 .74 .59 .54 .52 .64 .84
ATP .99 1.12 .99 1.16 1.22 .84 .93
KLA/ATP .75 .78 .58 .64 .62 .59 .77
Tgfbr2
KLA  ATP  ATP+KLA
 AK090393 10 days pregnant adult female ovary and uterus cDNA, RIKEN full-length enriched library, clone:G630098D03 product:transforming growth factor, beta receptor II, full insert sequence. [AK090393] KLA .98 .89 1.00 .96 .94 1.00 .92
ATP .99 .99 .90 .94 .93 .96 1.02
KLA/ATP .92 .96 .98 .98 .98 .95 1.01
Tgfbr2
KLA  ATP  ATP+KLA
 NM_009371 transforming growth factor, beta receptor II (Tgfbr2), transcript variant 1, mRNA [NM_009371] KLA .55 .50 .58 .50 .52 .55 .44
ATP .98 .75 .50 .32 .41 .29 .50
KLA/ATP .59 .45 .32 .23 .31 .27 .25
Tgfbr2
KLA  ATP  ATP+KLA
 NM_029575 transforming growth factor, beta receptor II (Tgfbr2), transcript variant 2, mRNA [NM_029575] KLA .95 .93 .99 .95 .88 1.02 .82
ATP .87 .93 .84 .84 .74 .72 1.00
KLA/ATP .89 .85 .83 .85 .76 .80 .79
Tpm3
KLA  ATP  ATP+KLA
 NM_022314 tropomyosin 3, gamma (Tpm3), mRNA [NM_022314] KLA 1.24 1.34 1.32 1.37 1.58 1.38 1.21
ATP 1.11 1.25 .97 1.43 1.09 .80 1.10
KLA/ATP 1.43 1.65 1.10 1.73 1.02 1.06 1.55
Tpr
KLA  ATP  ATP+KLA
 NM_133780 translocated promoter region (Tpr), mRNA [NM_133780] KLA 1.86 1.70 1.73 1.84 1.35 1.12 1.05
ATP 1.03 .93 1.16 .85 .90 1.16 .66
KLA/ATP 1.64 1.73 2.44 1.50 1.27 1.00 .83
Traf1
KLA  ATP  ATP+KLA
 NM_009421 Tnf receptor-associated factor 1 (Traf1), mRNA [NM_009421] KLA 44.86 39.03 38.11 34.21 36.49 19.69 14.75
ATP 1.14 1.04 1.98 8.16 16.79 30.81 6.36
KLA/ATP 46.20 45.67 45.63 38.00 27.26 31.47 63.83
Traf2
KLA  ATP  ATP+KLA
 NM_009422 Tnf receptor-associated factor 2 (Traf2), mRNA [NM_009422] KLA 3.38 3.62 3.49 3.36 3.49 3.39 2.68
ATP .97 1.04 1.00 1.10 1.54 2.40 1.55
KLA/ATP 3.38 3.16 2.93 2.74 2.67 3.11 4.70
Traf3
KLA  ATP  ATP+KLA
 NM_011632 Tnf receptor-associated factor 3 (Traf3), transcript variant 1, mRNA [NM_011632] KLA .52 .49 .51 .49 .80 .98 1.22
ATP .93 .92 .95 1.13 2.70 1.80 1.42
KLA/ATP .56 .50 .49 1.07 2.94 1.92 1.65
Traf4
KLA  ATP  ATP+KLA
 NM_009423 Tnf receptor associated factor 4 (Traf4), mRNA [NM_009423] KLA .88 .85 .85 .84 .86 .88 .91
ATP .98 1.01 1.01 .96 1.05 1.29 .93
KLA/ATP .83 .86 .83 .94 1.01 1.11 .88
Traf5
KLA  ATP  ATP+KLA
 NM_011633 Tnf receptor-associated factor 5 (Traf5), mRNA [NM_011633] KLA 1.82 1.92 1.93 2.10 2.75 2.08 1.00
ATP 1.02 1.04 1.10 .78 3.79 2.22 1.42
KLA/ATP 1.70 1.89 1.85 1.64 5.40 2.10 1.83
Traf6
KLA  ATP  ATP+KLA
 NM_009424 Tnf receptor-associated factor 6 (Traf6), mRNA [NM_009424] KLA 1.19 1.28 1.34 1.20 1.23 1.23 1.28
ATP 1.06 1.12 .92 1.15 2.46 1.84 1.40
KLA/ATP 1.32 1.37 .89 1.16 1.45 1.49 1.46
Trp53
KLA  ATP  ATP+KLA
 NM_011640 transformation related protein 53 (Trp53), mRNA [NM_011640] KLA 1.25 1.37 1.11 .86 .72 .71 .95
ATP 1.15 1.32 .90 1.85 1.26 .68 .70
KLA/ATP 1.66 1.49 .80 1.76 .81 .65 .74
Vegfa
KLA  ATP  ATP+KLA
 NM_001025250 vascular endothelial growth factor A (Vegfa), transcript variant 1, mRNA [NM_001025250] KLA .49 .48 .46 .46 .39 .64 1.18
ATP 1.05 1.37 3.82 10.55 12.51 24.20 7.85
KLA/ATP .48 .59 1.45 7.42 19.75 27.42 22.35
Vegfa
KLA  ATP  ATP+KLA
 NM_001025257 vascular endothelial growth factor A (Vegfa), transcript variant 3, mRNA [NM_001025257] KLA .72 .71 .66 .70 .65 .80 1.22
ATP 1.01 1.21 3.24 11.12 11.09 18.59 5.43
KLA/ATP .68 .71 1.47 5.94 15.06 20.32 17.31
Vegfb
KLA  ATP  ATP+KLA
 NM_011697 vascular endothelial growth factor B (Vegfb), mRNA [NM_011697] KLA .65 .63 .65 .63 .52 .38 .37
ATP 1.11 1.07 1.16 1.44 1.72 1.22 .43
KLA/ATP .67 .67 .89 .90 1.19 .86 .31
Vegfc
KLA  ATP  ATP+KLA
 NM_009506 vascular endothelial growth factor C (Vegfc), mRNA [NM_009506] KLA 2.07 2.21 2.04 3.27 2.51 1.73 2.90
ATP 1.08 1.03 1.24 1.32 2.55 5.18 2.58
KLA/ATP 2.20 2.29 2.72 2.97 4.35 4.24 5.06
Vhlh
KLA  ATP  ATP+KLA
 S76748 gb|mVHLh1=von Hippel-Lindau disease gene [mice, mRNA, 2757 nt]. [S76748] KLA 1.39 1.39 1.47 1.46 1.62 1.84 1.48
ATP .73 .64 .54 .55 1.44 2.26 1.44
KLA/ATP 1.17 1.13 .91 .73 1.72 2.26 2.16
Wnt1
KLA  ATP  ATP+KLA
 NM_021279 wingless-related MMTV integration site 1 (Wnt1), mRNA [NM_021279] KLA 1.01 1.01 1.05 1.03 1.04 1.04 1.01
ATP .99 .99 1.01 .97 .96 1.01 1.00
KLA/ATP 1.01 1.04 1.06 1.02 1.00 .98 .98
Wnt10a
KLA  ATP  ATP+KLA
 NM_009518 wingless related MMTV integration site 10a (Wnt10a), mRNA [NM_009518] KLA 1.73 1.66 1.33 1.17 1.10 1.02 1.03
ATP 1.03 1.04 .93 1.02 1.04 1.07 1.06
KLA/ATP 1.83 1.67 1.53 1.21 1.10 1.12 1.09
Wnt10b
KLA  ATP  ATP+KLA
 NM_011718 wingless related MMTV integration site 10b (Wnt10b), mRNA [NM_011718] KLA 1.10 .98 1.13 1.01 .96 1.00 .96
ATP 1.02 1.02 .99 1.01 .96 1.02 1.01
KLA/ATP 1.01 1.18 .97 .97 1.03 1.04 .98
Wnt11
KLA  ATP  ATP+KLA
 NM_009519 wingless-related MMTV integration site 11 (Wnt11), mRNA [NM_009519] KLA .97 1.00 .97 1.03 1.16 1.08 1.11
ATP 1.03 1.06 1.08 1.23 1.13 1.03 1.08
KLA/ATP .95 1.00 .95 1.02 .97 1.04 1.04
Wnt16
KLA  ATP  ATP+KLA
 NM_053116 wingless-related MMTV integration site 16 (Wnt16), mRNA [NM_053116] KLA 1.00 1.02 .97 1.02 .96 1.02 1.05
ATP 1.01 1.00 .97 .98 .97 .95 1.02
KLA/ATP .96 1.01 .98 1.03 .99 1.00 .97
Wnt2
KLA  ATP  ATP+KLA
 NM_023653 wingless-related MMTV integration site 2 (Wnt2), mRNA [NM_023653] KLA 1.01 1.00 1.02 .96 1.06 1.03 .94
ATP .97 1.01 1.02 .98 1.00 1.05 1.01
KLA/ATP .97 .94 1.03 1.02 1.00 .99 1.05
Wnt2b
KLA  ATP  ATP+KLA
 NM_009520 wingless related MMTV integration site 2b (Wnt2b), mRNA [NM_009520] KLA 1.04 1.03 .99 1.01 .95 1.02 .99
ATP .95 1.00 .95 .99 .97 1.03 1.01
KLA/ATP 1.02 .99 1.01 1.06 .99 .99 1.02
Wnt3
KLA  ATP  ATP+KLA
 NM_009521 wingless-related MMTV integration site 3 (Wnt3), mRNA [NM_009521] KLA 1.04 1.02 1.04 1.02 1.00 .99 1.00
ATP 1.03 .98 1.04 1.04 .96 1.00 1.02
KLA/ATP 1.03 .99 .98 1.03 1.04 .94 1.03
Wnt3a
KLA  ATP  ATP+KLA
 NM_009522 wingless-related MMTV integration site 3A (Wnt3a), mRNA [NM_009522] KLA 1.01 1.00 1.06 1.02 .99 1.02 .99
ATP .96 .97 1.05 1.04 1.02 1.02 1.04
KLA/ATP 1.02 1.03 .96 1.01 .99 1.06 1.00
Wnt4
KLA  ATP  ATP+KLA
 NM_009523 wingless-related MMTV integration site 4 (Wnt4), mRNA [NM_009523] KLA 1.01 1.01 .97 1.06 1.12 1.02 .93
ATP 1.02 1.06 1.03 1.02 1.00 1.02 .98
KLA/ATP .94 1.01 1.06 1.05 .96 .96 1.00
Wnt5a
KLA  ATP  ATP+KLA
 NM_009524 wingless-related MMTV integration site 5A (Wnt5a), mRNA [NM_009524] KLA .98 1.06 1.01 .96 1.03 1.02 1.07
ATP 1.01 .96 1.06 1.11 1.02 .97 1.03
KLA/ATP 1.05 .96 .96 1.04 1.12 1.06 .96
Wnt5b
KLA  ATP  ATP+KLA
 NM_009525 wingless-related MMTV integration site 5B (Wnt5b), mRNA [NM_009525] KLA 1.04 1.04 1.19 1.11 1.10 1.11 1.05
ATP 1.04 1.01 .95 1.01 .99 1.04 1.05
KLA/ATP 1.05 1.06 1.11 1.07 1.04 1.08 1.05
Wnt6
KLA  ATP  ATP+KLA
 M89800 gb|Mouse Wnt-6 mRNA, complete cds. [M89800] KLA 1.92 1.97 1.93 2.04 2.01 2.62 5.22
ATP .96 .97 1.07 1.03 .76 .94 1.18
KLA/ATP 2.04 1.91 1.96 1.72 1.40 1.31 2.45
Wnt6
KLA  ATP  ATP+KLA
 NM_009526 wingless-related MMTV integration site 6 (Wnt6), mRNA [NM_009526] KLA 2.83 2.51 2.19 2.74 2.92 3.01 5.82
ATP 1.01 .87 1.07 .77 .59 1.11 1.06
KLA/ATP 2.31 2.49 2.69 1.79 1.63 1.26 2.64
Wnt7a
KLA  ATP  ATP+KLA
 NM_009527 wingless-related MMTV integration site 7A (Wnt7a), mRNA [NM_009527] KLA .96 .92 .91 .99 .96 .98 .97
ATP 1.05 .95 .98 .98 1.03 .98 1.11
KLA/ATP .92 .89 .88 .97 1.01 1.04 1.01
Wnt7b
KLA  ATP  ATP+KLA
 NM_009528 wingless-related MMTV integration site 7B (Wnt7b), mRNA [NM_009528] KLA 1.06 1.09 .99 1.09 1.06 1.19 1.26
ATP .99 .98 1.02 1.08 1.02 1.11 1.54
KLA/ATP 1.02 1.01 .99 1.14 1.07 1.09 1.58
Wnt8a
KLA  ATP  ATP+KLA
 NM_009290 wingless-related MMTV integration site 8A (Wnt8a), mRNA [NM_009290] KLA .92 1.01 .99 1.00 1.06 1.01 1.04
ATP 1.00 1.01 1.01 1.04 1.00 1.06 1.05
KLA/ATP 1.07 1.05 .99 1.08 1.07 1.09 1.07
Wnt8b
KLA  ATP  ATP+KLA
 NM_011720 wingless related MMTV integration site 8b (Wnt8b), mRNA [NM_011720] KLA 1.00 1.00 .94 1.03 .98 .98 .97
ATP .99 1.01 1.01 1.01 1.05 1.04 1.03
KLA/ATP .98 1.03 1.00 1.01 .99 1.02 1.02
Wnt9a
KLA  ATP  ATP+KLA
 NM_139298 wingless-type MMTV integration site 9A (Wnt9a), mRNA [NM_139298] KLA .93 .95 .95 1.01 .96 .97 1.01
ATP 1.01 .98 1.01 1.08 1.43 1.02 1.44
KLA/ATP .94 .96 1.03 1.15 1.43 1.15 1.21
Wnt9b
KLA  ATP  ATP+KLA
 NM_011719 wingless-type MMTV integration site 9B (Wnt9b), mRNA [NM_011719] KLA .97 1.00 .94 1.00 .99 .97 1.02
ATP .96 1.02 1.05 .99 .92 1.11 1.08
KLA/ATP .97 .96 .99 .93 .96 1.03 .99
Xiap
KLA  ATP  ATP+KLA
 NM_009688 X-linked inhibitor of apoptosis (Xiap), mRNA [NM_009688] KLA 1.61 1.63 1.62 1.52 1.34 1.27 1.11
ATP 1.03 1.01 .99 .96 .88 1.19 1.25
KLA/ATP 1.64 1.63 1.54 1.33 1.08 1.19 1.72